doxazosin has been researched along with Hypertension in 471 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone was the most effective add-on drug for the treatment of resistant hypertension." | 9.20 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2015) |
| "The PATHWAY-2 study, funded by the British Heart Foundation, randomised 335 patients with resistant hypertension (already treated according to guidelines) to sequentially receive 12 weeks of spironolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin (4-8 mg modified release) and placebo." | 9.20 | [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension]. ( Widimský, J, 2015) |
| "To determine the role of home blood pressure (BP) monitoring for a reproducible assessment of orthostatic hypertension (OHT) and the effectiveness of hypertension control by doxazosin." | 9.16 | Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin. ( Eguchi, K; Hoshide, S; Kario, K; Matsui, Y; Parati, G; Shibazaki, S, 2012) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "This study was designed to determine whether or not the addition of a single nighttime dose of doxazosin in extended-release form (GITS; gastrointestinal therapeutic system) would affect the autonomic modulation of the cardiovascular system in patients with uncontrolled hypertension treated with a multi-drug regimen." | 9.13 | Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system. ( Adamska, K; Guzik, P; Krauze, T; Milewska, A; Piskorski, J; Wesseling, KH; Wykretowicz, A; Wysocki, H, 2008) |
| "In this prospective, ex vivo, single-blind study, the effect of doxazosin on platelet function was studied in patients with hypertension." | 9.12 | Effect of doxazosin gastrointestinal therapeutic system on platelet degranulation and platelet-leukocyte microaggregate formation induced by physiologic shear stress in hypertension. ( Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, M, 2006) |
| "The aim of this trial was to evaluate the effect of doxazosin as add-on therapy in patients with hypertension not adequately controlled on current antihypertensive therapy, and impaired glucose metabolism." | 9.12 | Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. ( Ciccariello, L; Gussoni, G; Muggeo, M; Perrone, F; Pessina, AC; Scotti, A; Stoico, V, 2006) |
| "To evaluate extended-release doxazosin gastrointestinal therapeutic system (GITS) as add-on therapy in patients with treated, but uncontrolled hypertension." | 9.12 | Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study. ( de Alvaro, F; Hernández-Presa, MA, 2006) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 9.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 9.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "The selective alpha 1-adrenoceptor antagonist doxazosin in both standard formulation and gastrointestinal therapeutic system (GITS) controlled-release formulation is effective for hypertension without having a negative impact on serum lipids." | 9.11 | Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. ( Armada, B; Calvo, C; Gil-Extremera, B; Gomez-Fernández, P; Masramon, X; Pueyo, C, 2005) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 9.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| " Doxazosin, a selective alpha(1)-adrenergic blocker, in addition to lowering blood pressure, has been shown to have positive effects on glucose metabolism and lipid profiles in patients with hypertension." | 9.11 | Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. ( Collins, B; Hobbs, FR; Khan, T, 2005) |
| "To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH)." | 9.11 | Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. ( Castaño, I; Duran, R; Hernandez, C; Jara, J; Moralejo, M, 2005) |
| "To investigate the effect of the doxazosin gastrointestinal therapeutic system (GITS) on the 24 h blood pressure (BP) profile by ambulatory blood pressure measurements (ABPM) in patients with stage 1 to stage 2 primary hypertension." | 9.10 | Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension. ( Lemmer, B; Nold, G, 2003) |
| "We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 9.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
| "The alpha 1-blocker doxazosin is a well-established therapy for hypertension and benign prostatic hyperplasia; however, in its standard form, a multiple-step titration regimen is usually required." | 9.09 | Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. ( Os, I; Stokke, HP, 1999) |
| "The alpha1-adrenoceptor antagonist doxazosin has proved successful in treating patients with concurrent benign prostatic hyperplasia (BPH) and hypertension in short-term studies." | 9.09 | Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. ( Cook, E; Fawzy, A; Gonzalez, F; Hendry, A, 1999) |
| "Doxazosin, an effective treatment for mild-to-moderate hypertension and benign prostatic hyperplasia, in its standard formulation requires a multiple-step titration regimen to minimize the potential for first-dose effects." | 9.09 | Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. ( Os, I; Stokke, HP, 1999) |
| " Doxazosin and amlodipine, alone and in combination, were compared for efficacy in reducing blood pressure (BP) in 75 patients with predominantly moderate (Stage 2) hypertension." | 9.09 | Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. ( Nalbantgil, I; Nalbantgil, S; Onder, R, 2000) |
| "To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH)." | 9.08 | Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. ( Kirby, RS, 1995) |
| "To compare the effects of doxazosin on blood pressure when used for the treatment of benign prostatic hyperplasia (BPH) in men who are either physiologically or pharmacologically normotensive." | 9.08 | Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. ( Kaplan, SA; Meade-D'Alisera, P; Quiñones, S; Soldo, KA, 1995) |
| "This is an open non-comparative study to evaluate the efficacy and tolerability of doxazosin mesilate in 540 subjects with either history or newly diagnosed mild/moderate hypertension." | 9.08 | [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study]. ( Pessina, AC, 1995) |
| "The effect of both administration and withdrawal of doxazosin on patients with essential hypertension was evaluated by twenty-four-hour ambulatory blood pressure (BP) monitoring." | 9.08 | Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension. ( Fujishima, M; Hirota, Y; Ito, Y; Takata, Y; Yoshizumi, T, 1995) |
| "The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting." | 9.08 | Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996) |
| "Aim of the study was to evaluate the effects of a 6 month treatment with doxazosin on blood pressure profile, left ventricular morphology and function and microalbuminuria in non diabetics patients with mild to moderate essential hypertension." | 9.08 | [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension]. ( Bignotti, M; Lamponi, M, 1996) |
| "We evaluated the sustained efficacy and safety of doxazosin for long-term treatment (up to 48 months) of normotensive and hypertensive patients with benign prostatic hyperplasia (BPH)." | 9.08 | Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. ( Dias, N; Fawzy, A; Gaffney, M; Ice, K; Kaplan, SA; Klimberg, I; Lepor, H; Mobley, DF, 1997) |
| "Doxazosin, an alfa-1 adrenoceptor antagonist, was compared with nitrendipine, a calcium antagonist, to evaluate their efficacy and safety in 61 patients with mild to moderate hypertension." | 9.08 | [Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension]. ( Espejo Martínez, J; Sanz Guajardo, D, 1997) |
| "To investigate the effects of doxazosin on blood pressure and sympathetic nervous activity, we analyzed the circadian variation of blood pressure and the power spectrum of R-R intervals using an ambulatory multibiomedical monitoring system (TM2425) in 10 untreated outpatients with essential hypertension." | 9.08 | Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension. ( Ishii, M; Kawano, Y; Miyajima, E; Tochikubo, O; Watanabe, Y, 1997) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 9.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "9 mg) of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 111 patients with mild hypertension." | 9.07 | Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. ( Levenstein, M; Pickering, TG; Walmsley, P, 1994) |
| "In this study the effects of a single daily dose of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 112 patients with mild hypertension." | 9.07 | Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. ( Levenstein, M; Pickering, TG; Walmsley, P, 1994) |
| "When doxazosin was given to patients with hypertension not adequately controlled by beta-blockade, blood pressure was normalized in 94% of the 34 patients (blood pressure less than or equal to 140/85 mm Hg)." | 9.07 | The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. ( Barlage, U; Englert, RG, 1991) |
| "This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)." | 9.07 | Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991) |
| "This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting." | 9.07 | A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991) |
| "This study assessed the long-term (54 weeks) antihypertensive efficacy and safety of doxazosin in the treatment of mild or moderate essential hypertension, defined as sitting and standing diastolic blood pressure of 95 to 114 mm Hg." | 9.07 | A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice. ( Manos, J, 1991) |
| "Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2." | 9.07 | Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. ( Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 9.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| " Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)." | 9.07 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991) |
| "This study assessed the efficacy and safety of once-daily doxazosin in the treatment of patients (n = 19) with mild or moderate essential hypertension (sitting diastolic blood pressure [DBP] 95 to 114 mm Hg) and concomitant intermittent claudication (Doppler ankle/arm ratio of less than 0." | 9.07 | A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication. ( Catalano, M; Libretti, A, 1991) |
| "Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension." | 9.06 | Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. ( Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A, 1990) |
| "The efficacy and tolerability of doxazosin and atenolol in the management of mild and moderate hypertension were compared in a multicentre, parallel study, the first year of which was randomized and double-blind." | 9.06 | A long-term study of atenolol and doxazosin in mild and moderate hypertension. ( Daae, L; Talseth, T; Westlie, L, 1990) |
| "The antihypertensive effect and safety of doxazosin once-daily was compared with that of atenolol once-daily in 40 patients with mild to moderate hypertension." | 9.06 | Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Staessen, J, 1988) |
| "The antihypertensive effect and safety of doxazosin once daily as well as the effect on serum lipids was compared with that of atenolol once daily in 40 patients with mild to moderate hypertension." | 9.06 | Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Lissens, W; Staessen, J, 1989) |
| "The effects of once-daily therapy with doxazosin (1 to 8 mg/day) on exercise capacity, left ventricular performance and hemodynamics (radionuclide ventriculography) were compared with those of atenolol (50 to 100 mg/day) and placebo in a randomized, double-blind crossover trial in 16 patients (9 men) with mild hypertension." | 9.06 | Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function. ( Bautovich, GJ; Fletcher, PJ; Gillin, AG; Horvath, JS; Hutton, BF; Tiller, DJ, 1989) |
| " This study investigates aspects of the pharmacokinetics, pharmacodynamics and concentration-effect relationships in 10 patients with essential hypertension during acute and chronic treatment with doxazosin, an alpha 1-adrenoceptor antagonist." | 9.06 | Concentration-effect relationships and individual responses to doxazosin in essential hypertension. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1989) |
| "The long-term safety, efficacy and effect on serum lipid profile of doxazosin, a new alpha 1-adrenoceptor inhibitor administered once daily, were compared with those of prazosin, administered twice daily, in 104 patients with essential hypertension treated for 1 year." | 9.06 | An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1987) |
| "9 mg, range 1 to 16) in the treatment of essential hypertension were compared in a double-blind study with those of hydrochlorothiazide (HCTZ) (mean dosage, 84." | 9.06 | Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. ( Claessens, J; Nelemans, F; Riesen, W; Streulens, Y; Trost, BN; Weidmann, P, 1987) |
| "A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension." | 9.06 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986) |
| "The efficacy and safety of doxazosin (DOX) for the treatment of hypertension was investigated." | 9.06 | Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. ( Bloomfield, R; Cubeddu, LX; Halperin, A; Klotman, PE; Nelson, EB; Pickering, BI; Pool, JL; Wombolt, DG, 1988) |
| "The purpose of this article is to review the role of doxazosin in the current treatment of hypertension." | 8.84 | Doxazosin in the current treatment of hypertension. ( Guzik, P; Wykretowicz, A; Wysocki, H, 2008) |
| "The purpose of this paper is to review the role of doxazosin, a long-acting alpha(1)-blocker, as a component of combination therapy for patients with stage 1 and stage 2 hypertension and for patients with concomitant hypertension and hyperlipidemia or glucose intolerance." | 8.82 | Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. ( Black, HR, 2003) |
| "Doxazosin is an effective treatment for patients with hypertension, benign prostatic hyperplasia (BPH) and the two comorbidly." | 8.82 | Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. ( Kirby, RS; Lund-Johansen, P, 2003) |
| "Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline." | 8.82 | Clinical ease of using doxazosin in BPH patients with and without hypertension. ( Kirby, RS; Steers, WD, 2005) |
| "In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs." | 7.88 | Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2018) |
| " The cohort was divided into three groups - a reference group of no α-blocker therapy (n = 17 ,053), α blockers for benign prostatic hypertrophy (BPH) (n = 1164), and doxazosin for hypertension (HTN) (n = 1258)." | 7.80 | Doxazosin to treat hypertension: it's time to take it personally--a retrospective analysis of 19, 495 patients. ( Novack, V; Shalev, A; Sharon, A; Toledano, R; Wolak, A; Wolak, T, 2014) |
| "Authors evaluated the effects of selective adrenergic blockade by means of doxazosin on blood pressure in 48 patients operated on for pheochromocytoma by a multicenter retrospective study." | 7.79 | Role of preoperative adrenergic blockade with doxazosin on hemodynamic control during the surgical treatment of pheochromocytoma: a retrospective study of 48 cases. ( Agostino-Sinisi, A; Conzo, G; Corcione, F; Della-Pietra, C; Depalma, M; Ferraro, F; Milone, M; Musella, M; Napolitano, S; Palazzo, A; Pasquali, D; Santini, L; Stanzione, F, 2013) |
| "Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist structurally related to prazosin." | 7.76 | Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. ( Brogden, RN; Young, RA, 1988) |
| "The aim of this study was to evaluate the use of spironolactone and doxazosin as treatment for patients with resistant hypertension." | 7.75 | Spironolactone and doxazosin treatment in patients with resistant hypertension. ( Baldó, E; Costa, JA; González, C; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E, 2009) |
| " The purpose of this study was to evaluate the effect of the alpha(1)-adrenoceptor antagonist, doxazosin mesilate, on cerebral blood flow (CBF) and flow velocity in the common carotid artery in patients with hypertension and chronic cerebral infarction." | 7.75 | The effect of doxazosin mesilate on cerebral blood flow in patients with hypertension and chronic cerebral infarction. ( Katayama, Y; Usuda, K, 2009) |
| "Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development." | 7.75 | Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. ( Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009) |
| "Twenty patients with inadequately controlled hypertension were treated with 4 mg doxazosin ER daily for 16 weeks as an adjunct to their existing antihypertensive regimen." | 7.74 | Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation. ( Adamska, K; Guzik, P; Krauze, T; Milewska, A; Wykretowicz, A; Wysocki, H, 2007) |
| " The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy." | 7.74 | Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007) |
| "To evaluate the vascular effects of doxazosin, an alpha-1 antagonist, in hypertensive patients with metabolic syndrome in whom the drug has previously been shown to exert beneficial metabolic actions on lipids and insulin metabolism." | 7.73 | The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Pellegrini, G; Penno, G; Pucci, L; Scotti, A, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 7.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| "To assess the long-term efficacy and safety of extended-release doxazosin gastrointestinal therapeutic system (GITS) under routine clinical care conditions over 12 months in Korean men with benign prostatic hyperplasia (BPH) with and without coexisting hypertension." | 7.73 | Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. ( Chung, BH; Hong, SJ, 2006) |
| "There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH)." | 7.72 | [Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension]. ( Aliaga Martínez, L; Fernández-Torres, C; Jiménez-Alonso, J; Mediavilla García, JD; Sabio, JM, 2004) |
| "A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus." | 7.71 | [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. ( Hoogenberg, K; van der Tuin, J, 2002) |
| "The aim of the present study was to analyse the nitric oxide (NO)/cyclic GMP (cGMP) relaxing system in spontaneously hypertensive rats of the stroke-prone substrain (SHRSP)." | 7.71 | Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin. ( Casado, S; de Andrés, R; Fortes, J; García-Colis, E; Gomez, J; López-Blaya, A; López-Farré, A; Rico, L; Rodriguez-Feo, JA, 2002) |
| "The goals of this study were to evaluate the tolerability and effectiveness of (1) using doxazosin in the standard and new GITS formulations in adult patients with hypertension who either had uncontrolled or newly diagnosed disease, and (2) replacing standard-formulation doxazosin with doxazosin in the GITS formulation." | 7.71 | A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. ( Anegón, M; Esteban, J; Gil de Miguel, A; Jiménez-García, R; Martínez, J; Sanz de Burgoa, V, 2002) |
| "Forty-six African patients with essential hypertension aged 40 to 65 years had plasma total cholesterol and triglyceride levels determined at four different periods during a 12-month treatment with doxazosin." | 7.70 | Influence of baseline values. I: Effects on plasma total cholesterol and triglyceride levels during doxazosin treatment for hypertension. ( Agbedana, EO; Ahaneku, JE; Salako, LA; Taylor, GO; Walker, O, 1998) |
| "The objective of the present study was to examine the effects of administration of an alpha 1-adrenoceptor antagonist, doxazosin, for 7 days on cerebral blood flow and the autoregulatory response to hypotension in anesthetized spontaneously hypertensive rats." | 7.69 | The alpha 1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagic hypotension in anesthetized hypertensive rats. ( Cai, H; Fujishima, M; Ibayashi, S; Sadoshima, S; Sugimori, H; Yao, H, 1995) |
| "The fibrinolytic and metabolic changes associated with doxazosin treatment were evaluated in 20 patients with mild to moderate hypertension." | 7.69 | Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Sheu, WH; Shieh, SM, 1996) |
| "The aim of the study was to investigate the effect of a new selective alpha 1-adrenoreceptor blocker doxazosin on blood pressure, serum lipids and lipoproteins in patients with essential hypertension." | 7.68 | [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism]. ( Chotkowska, E; Cybulska, I; Galewicz, A; Janaszek-Sitkowska, H; Peczkowska, M; Sawicki, M; Sznajderman, M; Wiernikowska-Wegorek, I, 1993) |
| "Doxazosin, an alpha-adrenergic antagonist with potentially favourable effects on lipid status was evaluated in 25 otherwise healthy general practice patients with mild to moderate hypertension." | 7.68 | Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group. ( , 1992) |
| "The metabolic changes associated with doxazosin treatment of hypertension were evaluated in ten patients with mild hypertension (mean +/- SEM = 150 +/- 3/100 +/- 1 mm Hg) and a plasma triglyceride (TG) concentration > 1." | 7.68 | Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. ( Chen, YD; Fuh, MM; Reaven, GM; Shen, DC; Sheu, WH; Shieh, SM, 1992) |
| " The pharmacokinetics of doxazosin, following a single oral dose (1 mg) and chronic oral dosing (doubling doses up to a maximum of 16 mg day-1), were studied in 18 patients with mild to moderate hypertension and stable renal function varying from normal to severely impaired." | 7.68 | The pharmacokinetics of doxazosin in patients with hypertension and renal impairment. ( Dewhurst, AG; Honeywell, R; Oliver, RM; Renwick, AG; Upward, JW; Waller, DG, 1990) |
| "A single dose of doxazosin, a long-acting postsynaptic alpha 1-adrenoceptor antagonist, was administered to seven patients with essential hypertension." | 7.67 | Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ( Kaneko, Y; Miyajima, E; Miyakawa, T; Shionoiri, H; Takagi, N; Umemura, S; Yasuda, G; Yoshimura, H, 1987) |
| "Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension." | 7.67 | Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988) |
| "Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension." | 7.67 | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988) |
| "The acute and chronic haemodynamic effects of doxazosin were studied in 14 patients (10 males, four females) with essential hypertension, at rest supine and sitting and during 100 W bicycling exercise." | 7.67 | Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. ( Haugland, H; Lund-Johansen, P; Omvik, P, 1986) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 6.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "Doxazosin GITS was increased to 8 mg/d after 2 or 4 weeks if patients did not respond (sitting blood pressure <140/90 mm Hg and 10/10-mm Hg decrease from baseline)." | 6.72 | Controlled-release doxazosin as combination therapy in hypertension: the GATES study. ( Black, HR; Bullen, K; Keck, M; Koren, A; Meredith, P; Quinn, S, 2006) |
| "Nitrites/nitrates were significantly lower (P < 0." | 6.72 | Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Galli, S; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Salvadeo, S; Tinelli, C, 2006) |
| "Doxazosin GITS is a safe agent which can reduce cardiovascular risk." | 6.71 | Doxazosin GITS trough to peak ratio and 24-hour blood pressure monitoring in the management of hypertension in renal transplant patients. ( Grinyó, JM; Ibernón, M; Martínez Castelao, A; Moreso, F; Rama, I; Sanz, V; Sarrias, X, 2003) |
| "Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients." | 6.71 | Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. ( Chung, BH; Hong, SJ; Lee, MS, 2005) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 6.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 6.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study." | 6.68 | Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. ( Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995) |
| " After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks." | 6.68 | [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. ( Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995) |
| " Terazosin, an alpha 1-adrenergic blocking agent, was given initially at the dosage of 1 mg daily." | 6.68 | Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. ( Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R, 1996) |
| "Both doxazosin and HCTZ were effective drugs over 1 year for treating hypertension." | 6.68 | Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. ( Flack, JM; Gonzalez, NM; Grimm, RH; Liebson, PR; Schoenberger, JA, 1996) |
| "Doxazosin was given in doses of 1 mg per day initially, then increased weekly to 2, 4, 8, and 16 mg, until goal blood pressure or maximum dose was reached or side effects limited further increase." | 6.68 | Neural mechanisms in primary hypertension. Efficacy of alpha-blockade with doxazosin during stress. ( DeQuattro, V; Lee, D; Lu, ZW, 1996) |
| "Essential hypertension is characterized by an insulin-resistance state that may be responsible for the increased atherogenesis typical of this disease." | 6.67 | Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. ( Appendino, M; Giorda, C, 1993) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 6.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Both doxazosin and prazosin were well tolerated; seven patients (5." | 6.67 | A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension. ( Fukiyama, K; Iimura, O; Ijichi, H; Inagaki, Y; Ishii, M; Kaneko, Y; Omae, T; Yagi, S; Yamada, K; Yoshinaga, K, 1991) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 6.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "With doxazosin treatment, the mean supine and standing SBPs were reduced by 15 mmHg and 13 mmHg, respectively." | 6.67 | An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency. ( Anderton, JL; Notghi, A, 1990) |
| " Starting at one mg, dosage was doubled every 2 weeks during a 10-week treatment period to a maximum dose of 16 mg once daily." | 6.66 | Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins. ( Ames, RP; Kiyasu, JY, 1989) |
| " Another multicenter trial reported that doxazosin therapy was effective at low doses; 76% of those responders achieved controlled blood pressure at a mean dosage of 3." | 6.66 | Efficacy and safety of doxazosin in hypertension therapy. ( Hayduk, K, 1987) |
| "Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension." | 6.66 | Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. ( Pool, JL, 1987) |
| "Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels." | 6.66 | A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. ( Black, H; Nash, DT; Reeves, RL; Schonfeld, G; Weidler, DJ, 1987) |
| "Doxazosin is an effective, well-tolerated, once-daily antihypertensive agent; it is comparable with terazosin but at a lower daily dosage." | 6.66 | Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. ( Hayduk, K; Schneider, HT, 1987) |
| "Doxazosin monotherapy was effective in eight of 12 patients (66." | 6.66 | Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. ( Miura, Y; Yoshinaga, K, 1988) |
| "Doxazosin is a new quinazoline derivative that, like prazosin, has selectivity for alpha 1-receptors." | 6.66 | Clinical pharmacology of doxazosin in patients with essential hypertension. ( Caplan, N; Cubeddu, LX; Ferry, D; Fuenmayor, N, 1987) |
| "The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients." | 6.66 | Doxazosin in patients with hypertension. ( Conrad, KA; Fagan, TC; Falkner, FC; Lazar, JD; Lee, S; Mackie, MJ; Mayshar, PV; Souhrada, JF, 1988) |
| "The prevalence of both benign prostatic hyperplasia (BPH) and hypertension increases with advancing age." | 6.41 | The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. ( Flack, JM, 2002) |
| "Doxazosin has been shown to be effective in reducing the symptoms of BPH in elderly patients whose blood pressure is well controlled by concomitant antihypertensive medication." | 6.41 | Doxazosin in elderly patients with hypertension. ( Fawzy, A; Weinberger, MH, 2000) |
| "Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin." | 6.39 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. ( Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995) |
| "Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment." | 6.39 | Profile of doxazosin in patients with benign prostatic hyperplasia. ( Janknegt, RA, 1995) |
| "Doxazosin therapy was associated with a trend toward correcting the disturbances of lipoprotein metabolism characteristic of NIDDM." | 6.38 | Doxazosin therapy in the treatment of diabetic hypertension. ( Feher, MD, 1991) |
| "The drug treatment of mild hypertension has been shown to afford protection against fatal and nonfatal strokes, congestive heart failure, progression to more severe levels of hypertension, and all-cause mortality, but not against the complications of coronary artery disease." | 6.38 | Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension. ( Davey, MJ, 1989) |
| "Control of high blood pressure has failed to reduce the risk of atherosclerotic coronary heart disease (CHD)." | 6.38 | Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. ( Nelson, EB; Pool, JL; Taylor, AA, 1989) |
| "The physicochemical properties, pharmacology, pharmacokinetics, cardiovascular and metabolic effects, adverse effects, dosage, and administration of doxazosin are described, and comparative clinical studies of doxazosin therapy in patients with mild to moderate hypertension are reviewed." | 6.17 | Doxazosin: a new alpha 1-adrenergic antagonist. ( Babamoto, KS; Hirokawa, WT, 1992) |
| "Doxazosin was usually added as the fifth antihypertensive drug in individuals who were either unresponsive to or intolerant of the combination of other antihypertensives." | 5.35 | Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. ( Ceral, J; Solar, M, 2009) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 5.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| "Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy." | 5.31 | The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. ( Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001) |
| "Doxazosin treatment prevented impaired vasodilatory response to SNP." | 5.31 | [Doxazosin and soluble guanylate cyclase in a rat model of hypertension]. ( Cabestrero, F; Casado, S; de Andrés, R; Farré, J; Fortes, J; Gómez, J; López-Farré, A; Núñez, A; Rico, L; Rodríguez-Feo, JA, 2001) |
| "Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0." | 5.30 | Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. ( Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998) |
| "Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors." | 5.29 | Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. ( Kirby, RS, 1994) |
| "Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 5.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 5.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| " The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved." | 5.28 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992) |
| "Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be a suitable agent for treating these patients." | 5.28 | [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension]. ( Brusletto, B; Daae, LN; Holme, I; Kierulf, P; Syvertsen, JO; Westheim, A, 1991) |
| "Doxazosin is a postsynaptic alpha-1 adrenoceptor blocker suitable for once a day treatment regime." | 5.28 | [Doxazosin for the treatment of arterial hypertension]. ( Buzzaccarini, F; Casolino, P; Giusto, M; Mozzato, MG; Pessina, AC; Rubino, N; Semplicini, A; Serena, L; Valle, R, 1990) |
| " This doxazosin dosage reduced the diastolic blood pressure on average from 103 to 91 mmHg (P = 0." | 5.28 | Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. ( Biernacki, W; Flenley, DC, 1989) |
| " We examined the contribution of the angiotensin-converting enzyme inhibitor ramipril and the alpha 1-adrenergic receptor blocker doxazosin on blood pressure and on markers of inflammation and hemostasis in 59 individuals with mild-to-moderate hypertension randomized to receive double-blind ramipril 10 mg od or doxazosin 8 mg od for 12 weeks." | 5.27 | Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension. ( Ekholm, M; Gigante, B; Jekell, A; Kahan, T; Wallén, NH, 2018) |
| " Patients with mild-to-moderate hypertension (n = 61, age 54 ± 12 years, 34% women) received the angiotensin converting enzyme inhibitor ramipril 10 mg or the alpha 1-adrenoceptor blocker doxazosin 8 mg double-blind for 12 weeks." | 5.24 | The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study. ( Jekell, A; Kahan, T; Kalani, M, 2017) |
| " Doxazosin in the management of arterial hypertension was associated with a higher risk of cardiovascular disease, particularly heart failure, than chlorthalidone." | 5.22 | Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. ( Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022) |
| "For most adults with resistant hypertension, spironolactone is superior to doxazosin and bisoprolol as an adjunct to triple therapy." | 5.22 | PURLs: Resistant hypertension? Time to consider this fourth-line drug. ( Kaysin, A; Mounsey, A, 2016) |
| "Spironolactone was the most effective add-on drug for the treatment of resistant hypertension." | 5.20 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2015) |
| "The PATHWAY-2 study, funded by the British Heart Foundation, randomised 335 patients with resistant hypertension (already treated according to guidelines) to sequentially receive 12 weeks of spironolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin (4-8 mg modified release) and placebo." | 5.20 | [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension]. ( Widimský, J, 2015) |
| "To determine the role of home blood pressure (BP) monitoring for a reproducible assessment of orthostatic hypertension (OHT) and the effectiveness of hypertension control by doxazosin." | 5.16 | Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin. ( Eguchi, K; Hoshide, S; Kario, K; Matsui, Y; Parati, G; Shibazaki, S, 2012) |
| "In the present study, 611 treated hypertensive patients with morning hypertension were randomized into either a doxazosin group, for whom a once-daily bedtime dose of doxazosin was added to the current medication regimen, or a control group, who continued their current medication." | 5.14 | Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kabutoya, T; Kario, K; Matsui, Y; Pickering, TG; Shibasaki, S; Shimada, K, 2009) |
| "Lower heart failure (HF) rates in individuals taking chlorthalidone vs amlodipine, lisinopril, or doxazosin were unanticipated in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)." | 5.14 | Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? ( Barzilay, J; Cutler, JA; Dart, RA; Davis, BR; Graumlich, JF; Grimm, RH; Margolis, KL; Murden, RA; Piller, LB; Randall, OS, 2009) |
| "The effects and duration of action of bedtime administration of doxazosin 2 mg for 4 weeks on uncontrolled morning home hypertension were investigated." | 5.14 | Blood pressure-lowering effect and duration of action of bedtime administration of doxazosin determined by home blood pressure measurement. ( Asayama, K; Gonokami, K; Hara, A; Imai, Y; Katada, S; Kikuya, M; Kobayashi, M; Metoki, H; Obara, T; Ohkubo, T, 2010) |
| "The role of doxazosin in treatment of hypertension remains controversial." | 5.13 | Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. ( Chang, CL; Chapman, N; Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "This study was designed to determine whether or not the addition of a single nighttime dose of doxazosin in extended-release form (GITS; gastrointestinal therapeutic system) would affect the autonomic modulation of the cardiovascular system in patients with uncontrolled hypertension treated with a multi-drug regimen." | 5.13 | Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system. ( Adamska, K; Guzik, P; Krauze, T; Milewska, A; Piskorski, J; Wesseling, KH; Wykretowicz, A; Wysocki, H, 2008) |
| "The result suggested that the angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers and long-acting calcium antagonists were effective in treating essential hypertension, while the low-dose doxazosin, terazosin and torasemide can be used for combination therapy but not for monotherapy." | 5.12 | [Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring]. ( Cheng, XR; Hua, CX; Hua, L; Huang, Y; Kang, J; Li, N; Li, YS; Liu, H; Ming, GH; Pang, HM; Wang, L; Wu, Y; Xu, L; Xu, ZM, 2007) |
| "In this prospective, ex vivo, single-blind study, the effect of doxazosin on platelet function was studied in patients with hypertension." | 5.12 | Effect of doxazosin gastrointestinal therapeutic system on platelet degranulation and platelet-leukocyte microaggregate formation induced by physiologic shear stress in hypertension. ( Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, M, 2006) |
| "The aim of this trial was to evaluate the effect of doxazosin as add-on therapy in patients with hypertension not adequately controlled on current antihypertensive therapy, and impaired glucose metabolism." | 5.12 | Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. ( Ciccariello, L; Gussoni, G; Muggeo, M; Perrone, F; Pessina, AC; Scotti, A; Stoico, V, 2006) |
| "To evaluate extended-release doxazosin gastrointestinal therapeutic system (GITS) as add-on therapy in patients with treated, but uncontrolled hypertension." | 5.12 | Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study. ( de Alvaro, F; Hernández-Presa, MA, 2006) |
| " In Protocol 2, a 6-month randomized controlled trial using a subtherapeutic dose of the alpha(1)-adrenergic receptor antagonist doxazosin (1 mg/day) versus placebo in 86 patients with essential hypertension was performed to determine whether the increase in ROS formation by MNC was independent of BP." | 5.12 | Anxiety-induced plasma norepinephrine augmentation increases reactive oxygen species formation by monocytes in essential hypertension. ( Kiriike, N; Maeda, K; Matsui, T; Nakamura, M; Watanabe, T; Yasunari, K, 2006) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 5.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 5.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "We conducted ambulatory BP monitoring three times (twice at baseline and after nighttime dosing of the alpha1-blocker doxazosin) in 98 elderly hypertensive patients in whom the presence of silent cerebral infarcts (SCI) was assessed by brain magnetic resonance imaging." | 5.11 | Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system. ( Eguchi, K; Hoshide, S; Hoshide, Y; Ishikawa, J; Kario, K; Morinari, M; Pickering, TG; Shimada, K, 2004) |
| "The selective alpha 1-adrenoceptor antagonist doxazosin in both standard formulation and gastrointestinal therapeutic system (GITS) controlled-release formulation is effective for hypertension without having a negative impact on serum lipids." | 5.11 | Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. ( Armada, B; Calvo, C; Gil-Extremera, B; Gomez-Fernández, P; Masramon, X; Pueyo, C, 2005) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 5.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| " Doxazosin, a selective alpha(1)-adrenergic blocker, in addition to lowering blood pressure, has been shown to have positive effects on glucose metabolism and lipid profiles in patients with hypertension." | 5.11 | Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. ( Collins, B; Hobbs, FR; Khan, T, 2005) |
| "To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH)." | 5.11 | Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. ( Castaño, I; Duran, R; Hernandez, C; Jara, J; Moralejo, M, 2005) |
| "In high-risk patients with hypertension, the higher risk for heart failure while taking doxazosin compared with chlorthalidone is attenuated but not eliminated by adding other antihypertensive drugs." | 5.10 | Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t ( Cutler, JA; Davis, BR; Farber, MA; Felicetta, JV; Furberg, CD; Stokes, JD; Wright, JT, 2002) |
| " The objective of this study was to demonstrate functional and structural effects of doxazosin (DOX) on largevessel and small-vessel arterial elasticity in hypertension (HTN)." | 5.10 | Effect of doxazosin on arterial elasticity: functional versus structural changes. ( Bratteli, CW; Glasser, SP, 2002) |
| "Hypertension treatment with doxazosin or HCTZ resulted in a comparable change in arterial IMT after three years, in spite of differences in effect on plasma lipids." | 5.10 | Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. ( Birkenhägeri, JC; de Groot, E; de Heide, LH; de Ridder, MA; Hoogerbrugge, N; Jansen, H; Stijnen, T, 2002) |
| "To investigate the effect of the doxazosin gastrointestinal therapeutic system (GITS) on the 24 h blood pressure (BP) profile by ambulatory blood pressure measurements (ABPM) in patients with stage 1 to stage 2 primary hypertension." | 5.10 | Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension. ( Lemmer, B; Nold, G, 2003) |
| "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD." | 5.10 | Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( , 2003) |
| "We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 5.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
| "The alpha 1-blocker doxazosin is a well-established therapy for hypertension and benign prostatic hyperplasia; however, in its standard form, a multiple-step titration regimen is usually required." | 5.09 | Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. ( Os, I; Stokke, HP, 1999) |
| "The alpha1-adrenoceptor antagonist doxazosin has proved successful in treating patients with concurrent benign prostatic hyperplasia (BPH) and hypertension in short-term studies." | 5.09 | Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. ( Cook, E; Fawzy, A; Gonzalez, F; Hendry, A, 1999) |
| "Elevated levels of endothelin-1 (ET-1) and von Willebrand factor (vWF), both markers indicative of endothelial function, are associated with hypertension." | 5.09 | Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. ( Andersen, P; Arnesen, H; Aspelin, T; Kierulf, P; Seljeflot, I, 1999) |
| "Doxazosin, an effective treatment for mild-to-moderate hypertension and benign prostatic hyperplasia, in its standard formulation requires a multiple-step titration regimen to minimize the potential for first-dose effects." | 5.09 | Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. ( Os, I; Stokke, HP, 1999) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "This randomized, double-blind, placebo-controlled study evaluated the use of doxazosin as an add-on therapy for inadequately controlled hypertension." | 5.09 | The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. ( Black, HR; Garofalo, JL; Sollins, JS, 2000) |
| " Doxazosin and amlodipine, alone and in combination, were compared for efficacy in reducing blood pressure (BP) in 75 patients with predominantly moderate (Stage 2) hypertension." | 5.09 | Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. ( Nalbantgil, I; Nalbantgil, S; Onder, R, 2000) |
| " The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older." | 5.09 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH)." | 5.08 | Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. ( Kirby, RS, 1995) |
| "To compare the effects of doxazosin on blood pressure when used for the treatment of benign prostatic hyperplasia (BPH) in men who are either physiologically or pharmacologically normotensive." | 5.08 | Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. ( Kaplan, SA; Meade-D'Alisera, P; Quiñones, S; Soldo, KA, 1995) |
| "Each treatment was taken for 1 month, preceded by a 2-week single-blind run-in period, in which the patients received a low dose of doxazosin (study A) or enalapril (study B) to enable recruitment of patients with moderate or severe hypertension." | 5.08 | Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. ( Brown, MJ; Dickerson, JE, 1995) |
| "This is an open non-comparative study to evaluate the efficacy and tolerability of doxazosin mesilate in 540 subjects with either history or newly diagnosed mild/moderate hypertension." | 5.08 | [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study]. ( Pessina, AC, 1995) |
| "The effect of both administration and withdrawal of doxazosin on patients with essential hypertension was evaluated by twenty-four-hour ambulatory blood pressure (BP) monitoring." | 5.08 | Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension. ( Fujishima, M; Hirota, Y; Ito, Y; Takata, Y; Yoshizumi, T, 1995) |
| "Eighty-one adult Nigerians with essential hypertension were randomly allocated to receive doxazosin, hydrochlorothiazide/amloride, or amlodipine." | 5.08 | Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients. ( Agbedana, OE; Ahaneku, JE; Taylor, OG, 1995) |
| "The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting." | 5.08 | Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996) |
| "In a previous open study on the metabolic effects of doxazosin in patients with essential hypertension, subgroup analysis indicated that subjects with an accumulation of risk factors for coronary heart disease (high VLDL triglycerides, low HDL cholesterol and high fasting blood glucose) seemed to benefit most from the metabolic actions of doxazosin treatment." | 5.08 | Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. ( Andersson, PE; Lithell, H, 1996) |
| " In this multicenter open-label study, the long-term effects of doxazosin, an alpha 1-adrenergic receptor blocker, on serum lipids were prospectively investigated in 253 patients with essential hypertension." | 5.08 | Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. ( Ebihara, A; Fujimura, A; Ishimitsu, T; Murata, K; Saito, A; Sakamaki, T; Sugishita, Y; Yagi, S, 1996) |
| "Aim of the study was to evaluate the effects of a 6 month treatment with doxazosin on blood pressure profile, left ventricular morphology and function and microalbuminuria in non diabetics patients with mild to moderate essential hypertension." | 5.08 | [Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension]. ( Bignotti, M; Lamponi, M, 1996) |
| "We evaluated the sustained efficacy and safety of doxazosin for long-term treatment (up to 48 months) of normotensive and hypertensive patients with benign prostatic hyperplasia (BPH)." | 5.08 | Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. ( Dias, N; Fawzy, A; Gaffney, M; Ice, K; Kaplan, SA; Klimberg, I; Lepor, H; Mobley, DF, 1997) |
| "Doxazosin, an alfa-1 adrenoceptor antagonist, was compared with nitrendipine, a calcium antagonist, to evaluate their efficacy and safety in 61 patients with mild to moderate hypertension." | 5.08 | [Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension]. ( Espejo Martínez, J; Sanz Guajardo, D, 1997) |
| "Doxazosin, as a mono-therapy, was studied in 28 patients with mild to severe hypertension over a period of 8 weeks." | 5.08 | Open trial of doxazosin in hypertensive Africans: dose finding, efficacy and safety studies. ( Salako, LA; Sowunmi, A; Walker, O, 1996) |
| "To investigate the effects of doxazosin on blood pressure and sympathetic nervous activity, we analyzed the circadian variation of blood pressure and the power spectrum of R-R intervals using an ambulatory multibiomedical monitoring system (TM2425) in 10 untreated outpatients with essential hypertension." | 5.08 | Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension. ( Ishii, M; Kawano, Y; Miyajima, E; Tochikubo, O; Watanabe, Y, 1997) |
| "Doxazosin (tonocardin) treatment was given for 11 weeks to 33 NIDDM patients with concomitant hypertension." | 5.08 | [Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus]. ( Lazebnik, LB; Melichenko, SB; Serebrov, AN, 1998) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 5.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "The effect of doxazosin versus captopril on blood pressure, albuminuria, and left ventricular mass was studied in 33 hypertensive type-1 diabetic patients randomized to 6 months treatment with captopril (17 patients, mean daily dose 100 mg) or doxazosin (16 patients, mean daily dose 9 mg)." | 5.08 | Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months. ( Aanderud, S; Gerdts, E; Lund-Johansen, P; Myking, OL; Omvik, P; Svarstad, E, 1998) |
| "9 mg) of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 111 patients with mild hypertension." | 5.07 | Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group. ( Levenstein, M; Pickering, TG; Walmsley, P, 1994) |
| "In this study the effects of a single daily dose of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 112 patients with mild hypertension." | 5.07 | Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. ( Levenstein, M; Pickering, TG; Walmsley, P, 1994) |
| "Twenty patients with essential hypertension were randomised to a 7-week period of dose titration with doxazosin, 1-8mg/day or enalapril, 5-20mg/day." | 5.07 | Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. ( Boutagy, J; Johnston, HJ; Marwood, JF; Monaghan, JC; Okoro, EO; Stokes, GS, 1994) |
| "The central role of insulin resistance in patients with essential hypertension was the impetus for the present study, in which carbohydrate and lipid metabolism were examined before and after three months treatment with doxazosin (n = 14) and atenolol (n = 15)." | 5.07 | Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. ( Andersson, PE; Berne, C; Johansson, J; Lithell, H, 1994) |
| "A randomized double-blind trial comparing the alpha-adrenergic blocker doxazosin and the beta-adrenergic blocker atenolol was completed by 131 patients with mild to moderate hypertension." | 5.07 | Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. ( Carruthers, SG; Huff, MW; Newman, C; Rabkin, SW; Sim, D, 1994) |
| "In an open, non-comparative, multicenter trail performed by general practitioners, the efficacy and safety of doxazosin, an inhibitor of postsynaptic alpha 1-adrenoceptors, were studied in 924 patients with mild to moderate hypertension." | 5.07 | [Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin]. ( Ganzinger, U; Hitzenberger, G, 1993) |
| "4,260 patients were included in an open surveillance study simultaneously with the introduction of doxazosin for treatment of essential hypertension in Norway." | 5.07 | [Doxazosin (Carduran)--a research survey]. ( Christophersen, BO; Fauchald, P; Holme, I; Rugstad, HE; Stokke, HP; Stokke, O, 1993) |
| " In a controlled, randomized double-blind trial, 15 patients with essential hypertension were treated with enalapril 5-20 mg/day, or doxazosin 1-8 mg/day, during a 7 week dose titration phase." | 5.07 | Increase in serum total angiotensin-converting enzyme activity with enalapril therapy in humans: a controlled trial. ( Johnston, H; Marwood, JF; Monaghan, JC; Okoro, EO; Stokes, GS, 1992) |
| "Twenty-two patients with diabetes and hypertension were treated with Doxazosin." | 5.07 | Doxazosin in the management of hypertensive diabetes--a cautionary note (?). ( Daly, L; Devlin, JG; McLaughlin, B, 1992) |
| "The antihypertensive efficacy and safety of doxazosin (once daily) and prazosin (twice daily) were compared in patients with mild or moderate essential hypertension (diastolic blood pressure [DBP] 95 to 114 mm Hg) not adequately controlled by diuretics and beta-blockers." | 5.07 | A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics. ( de Planque, BA, 1991) |
| "When doxazosin was given to patients with hypertension not adequately controlled by beta-blockade, blood pressure was normalized in 94% of the 34 patients (blood pressure less than or equal to 140/85 mm Hg)." | 5.07 | The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. ( Barlage, U; Englert, RG, 1991) |
| "This study investigated the safety and efficacy of doxazosin treatment in a large population of patients (n = 336) with essential hypertension and assessed the effect of doxazosin on the serum lipid profile and the calculated risk of developing coronary heart disease." | 5.07 | Clinical experience with doxazosin in general medical practice in New Zealand. ( Maslowski, AH, 1991) |
| "This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)." | 5.07 | Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991) |
| "This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting." | 5.07 | A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991) |
| "This study was designed to investigate the efficacy and toleration of once-daily doxazosin in the treatment of essential hypertension (sitting diastolic blood pressure 95 to 115 mm Hg) in a general medical practice." | 5.07 | Clinical experience with doxazosin in general medical practice in The Netherlands. ( Harmse, DP, 1991) |
| "This study assessed the long-term (54 weeks) antihypertensive efficacy and safety of doxazosin in the treatment of mild or moderate essential hypertension, defined as sitting and standing diastolic blood pressure of 95 to 114 mm Hg." | 5.07 | A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice. ( Manos, J, 1991) |
| "Sixteen patients with mild or moderate essential hypertension received 1 to 8 mg/day of doxazosin (mean daily dose, 2." | 5.07 | Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study. ( Corral, JL; López, NC; Pecorelli, A; Rincón, LA; Terán, VD, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 5.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| " Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)." | 5.07 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991) |
| "This study assessed the efficacy and safety of once-daily doxazosin in the treatment of patients (n = 19) with mild or moderate essential hypertension (sitting diastolic blood pressure [DBP] 95 to 114 mm Hg) and concomitant intermittent claudication (Doppler ankle/arm ratio of less than 0." | 5.07 | A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication. ( Catalano, M; Libretti, A, 1991) |
| "Doxazosin (mean dose 11 mg) given once daily in combination with 100 mg atenolol (n = 44) was compared with placebo and atenolol (n = 43) in a double-blind, multicenter study in patients with mild to moderate essential hypertension." | 5.06 | Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. ( Christensen, CC; Dathan, R; Dean, S; Searle, M; Westheim, A, 1990) |
| "The efficacy and tolerability of doxazosin and atenolol in the management of mild and moderate hypertension were compared in a multicentre, parallel study, the first year of which was randomized and double-blind." | 5.06 | A long-term study of atenolol and doxazosin in mild and moderate hypertension. ( Daae, L; Talseth, T; Westlie, L, 1990) |
| "The antihypertensive effect and safety of doxazosin once daily as well as the effect on serum lipids was compared with that of atenolol once daily in 40 patients with mild to moderate hypertension." | 5.06 | Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison. ( Amery, A; Fagard, R; Lijnen, P; Staessen, J, 1990) |
| "The antihypertensive effect and safety of doxazosin once-daily was compared with that of atenolol once-daily in 40 patients with mild to moderate hypertension." | 5.06 | Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Staessen, J, 1988) |
| "The antihypertensive effect and safety of doxazosin once daily as well as the effect on serum lipids was compared with that of atenolol once daily in 40 patients with mild to moderate hypertension." | 5.06 | Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. ( Amery, A; Fagard, R; Lijnen, P; Lissens, W; Staessen, J, 1989) |
| "The effects of once-daily therapy with doxazosin (1 to 8 mg/day) on exercise capacity, left ventricular performance and hemodynamics (radionuclide ventriculography) were compared with those of atenolol (50 to 100 mg/day) and placebo in a randomized, double-blind crossover trial in 16 patients (9 men) with mild hypertension." | 5.06 | Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function. ( Bautovich, GJ; Fletcher, PJ; Gillin, AG; Horvath, JS; Hutton, BF; Tiller, DJ, 1989) |
| " This study investigates aspects of the pharmacokinetics, pharmacodynamics and concentration-effect relationships in 10 patients with essential hypertension during acute and chronic treatment with doxazosin, an alpha 1-adrenoceptor antagonist." | 5.06 | Concentration-effect relationships and individual responses to doxazosin in essential hypertension. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1989) |
| "The long-term safety, efficacy and effect on serum lipid profile of doxazosin, a new alpha 1-adrenoceptor inhibitor administered once daily, were compared with those of prazosin, administered twice daily, in 104 patients with essential hypertension treated for 1 year." | 5.06 | An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1987) |
| "9 mg, range 1 to 16) in the treatment of essential hypertension were compared in a double-blind study with those of hydrochlorothiazide (HCTZ) (mean dosage, 84." | 5.06 | Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. ( Claessens, J; Nelemans, F; Riesen, W; Streulens, Y; Trost, BN; Weidmann, P, 1987) |
| "The efficacy and toleration of doxazosin and atenolol were compared over a 52-week period in a double-blind, multicenter study of 228 patients with mild-to-moderate hypertension." | 5.06 | Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. ( Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988) |
| "A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension." | 5.06 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986) |
| "The effects on plasma lipids and apoproteins A-I and B of oral administration of doxazosin and atenolol over a 20-week period were studied in 42 patients with mild to moderate essential hypertension." | 5.06 | Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. ( Himanen, P; Lehtonen, A; Marniemi, J; Niittymäki, K; Saraste, M, 1986) |
| "Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist which has been shown to be effective and well tolerated in the treatment of hypertension given in once-daily doses as monotherapy for up to 1 year or as an adjunct to thiazide or beta-adrenoceptor blockers." | 5.06 | The antihypertensive effects of doxazosin: a clinical overview. ( Cox, DA; Leader, JP; Milson, JA; Singleton, W, 1986) |
| "The pharmacodynamics of doxazosin and atenolol were compared on single study days in 39 patients with mild to moderate hypertension receiving long-term double-blind treatment." | 5.06 | The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment. ( Faulkner, JK; Himanen, P; Karjalainen, U; Saraste, M, 1987) |
| "The efficacy and safety of doxazosin (DOX) for the treatment of hypertension was investigated." | 5.06 | Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. ( Bloomfield, R; Cubeddu, LX; Halperin, A; Klotman, PE; Nelson, EB; Pickering, BI; Pool, JL; Wombolt, DG, 1988) |
| "The antihypertensive efficacy of the new, once daily, alpha 1-adrenoceptor inhibitor, doxazosin, was compared with placebo in 40 patients with mild to moderate hypertension." | 5.06 | 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. ( Jackson, G; Lorimer, AR; Pringle, S; Smyth, P, 1988) |
| "Eleven patients with uncomplicated essential hypertension received increasing single daily doses of UK-33,274, a new alpha-1 adrenoceptor antagonist, and prazosin for 4 days, in a open cross-over study." | 5.05 | Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist. ( Birkenhäger, WH; de Leeuw, PW; Ligthart, JJ; Smout, AJ, 1982) |
| "To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery." | 4.87 | Risk factors for intraoperative floppy iris syndrome: a meta-analysis. ( Chatziralli, IP; Sergentanis, TN, 2011) |
| "The purpose of this article is to review the role of doxazosin in the current treatment of hypertension." | 4.84 | Doxazosin in the current treatment of hypertension. ( Guzik, P; Wykretowicz, A; Wysocki, H, 2008) |
| "The purpose of this paper is to review the role of doxazosin, a long-acting alpha(1)-blocker, as a component of combination therapy for patients with stage 1 and stage 2 hypertension and for patients with concomitant hypertension and hyperlipidemia or glucose intolerance." | 4.82 | Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. ( Black, HR, 2003) |
| "Doxazosin is an effective treatment for patients with hypertension, benign prostatic hyperplasia (BPH) and the two comorbidly." | 4.82 | Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. ( Kirby, RS; Lund-Johansen, P, 2003) |
| " Two studies, a placebo-controlled, double-blind trial (n = 70) and a community-based, open-label trial (n = 491) investigated the antihypertensive efficacy of doxazosin, a long-acting selective alpha1-adrenoceptor blocker, as add-on therapy for uncontrolled hypertension with other antihypertensive medications and in patients with concomitant benign prostatic hyperplasia (BPH) and treated but inadequately controlled hypertension, respectively." | 4.82 | Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia. ( Zusman, R, 2004) |
| "Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline." | 4.82 | Clinical ease of using doxazosin in BPH patients with and without hypertension. ( Kirby, RS; Steers, WD, 2005) |
| "For various reasons, the alpha 1-receptor blocker prazosin has been used infrequently as initial therapy for hypertension." | 4.78 | Alpha-blocker therapy of hypertension. An unfulfilled promise. ( Kaplan, NM; Khoury, AF, 1991) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| "Hydralazine, doxazosin, and verapamil are currently recommended by the Endocrine Society as acceptable bridging treatment in those in whom full cessation of antihypertensive medication is infeasible during screening for primary aldosteronism (PA)." | 4.31 | The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof. ( Alnazer, RM; de Leeuw, PW; Kroon, AA; Veldhuizen, GP, 2023) |
| "In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs." | 3.88 | Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2018) |
| " The cohort was divided into three groups - a reference group of no α-blocker therapy (n = 17 ,053), α blockers for benign prostatic hypertrophy (BPH) (n = 1164), and doxazosin for hypertension (HTN) (n = 1258)." | 3.80 | Doxazosin to treat hypertension: it's time to take it personally--a retrospective analysis of 19, 495 patients. ( Novack, V; Shalev, A; Sharon, A; Toledano, R; Wolak, A; Wolak, T, 2014) |
| "Doxazosin (Doxa) is an α1-selective adrenergic receptor (ADR) antagonist widely used, alone or in combination, to treat high blood pressure, benign prostatic hyperplasia symptoms, and recently has been suggested as a potential drug for prostate cancer prevention/treatment." | 3.79 | Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats. ( Andric, SA; Janjic, MM; Kostic, TS; Stojkov, NJ, 2013) |
| "Authors evaluated the effects of selective adrenergic blockade by means of doxazosin on blood pressure in 48 patients operated on for pheochromocytoma by a multicenter retrospective study." | 3.79 | Role of preoperative adrenergic blockade with doxazosin on hemodynamic control during the surgical treatment of pheochromocytoma: a retrospective study of 48 cases. ( Agostino-Sinisi, A; Conzo, G; Corcione, F; Della-Pietra, C; Depalma, M; Ferraro, F; Milone, M; Musella, M; Napolitano, S; Palazzo, A; Pasquali, D; Santini, L; Stanzione, F, 2013) |
| "A number of agents are now available to treat hypertension." | 3.76 | alpha 1-antagonists in the treatment of hypertension. ( Grimm, RH, 1989) |
| "Doxazosin is a long-acting selective alpha 1-adrenoceptor antagonist structurally related to prazosin." | 3.76 | Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. ( Brogden, RN; Young, RA, 1988) |
| "The aim of this study was to evaluate the use of spironolactone and doxazosin as treatment for patients with resistant hypertension." | 3.75 | Spironolactone and doxazosin treatment in patients with resistant hypertension. ( Baldó, E; Costa, JA; González, C; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E, 2009) |
| " The purpose of this study was to evaluate the effect of the alpha(1)-adrenoceptor antagonist, doxazosin mesilate, on cerebral blood flow (CBF) and flow velocity in the common carotid artery in patients with hypertension and chronic cerebral infarction." | 3.75 | The effect of doxazosin mesilate on cerebral blood flow in patients with hypertension and chronic cerebral infarction. ( Katayama, Y; Usuda, K, 2009) |
| "Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development." | 3.75 | Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. ( Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009) |
| "ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF)." | 3.74 | The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. ( Black, HR; Cushman, WC; Davis, BR; Einhorn, PT; Levy, D; Massie, BM; Nwachuku, CE; Piller, LB; Simpson, LM, 2007) |
| "Twenty patients with inadequately controlled hypertension were treated with 4 mg doxazosin ER daily for 16 weeks as an adjunct to their existing antihypertensive regimen." | 3.74 | Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation. ( Adamska, K; Guzik, P; Krauze, T; Milewska, A; Wykretowicz, A; Wysocki, H, 2007) |
| " The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy." | 3.74 | Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007) |
| "To evaluate the vascular effects of doxazosin, an alpha-1 antagonist, in hypertensive patients with metabolic syndrome in whom the drug has previously been shown to exert beneficial metabolic actions on lipids and insulin metabolism." | 3.73 | The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Pellegrini, G; Penno, G; Pucci, L; Scotti, A, 2005) |
| "To confirm that alpha1, beta adrenoceptor antagonists and angiotensin II type 1 receptor blockers (ARBs) have different abilities to attenuate progressive cardiac hypertrophy despite their comparable lowering of blood pressure, we compared the effect of these agents alone or in combination on hypertensive cardiac hypertrophy." | 3.73 | Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction ( Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T, 2005) |
| " We assessed the effects of doxazosin on 24-h BP and spectral analysis of heart rate variability in hypertensive Type 2 diabetic patients with macroalbuminuria and compared the results with those in hypertensive Type 2 diabetic patients with normoalbuminuria and non-diabetic patients with essential hypertension." | 3.73 | Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. ( Hasegawa, K; Kuji, T; Ogawa, N; Shimura, G; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "To assess the long-term efficacy and safety of extended-release doxazosin gastrointestinal therapeutic system (GITS) under routine clinical care conditions over 12 months in Korean men with benign prostatic hyperplasia (BPH) with and without coexisting hypertension." | 3.73 | Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. ( Chung, BH; Hong, SJ, 2006) |
| "Doxazosin showed a good antihypertensive effect in CRF patients when used as third drug in resistant severe hypertension." | 3.73 | [Doxazosine associated to renin-angiotensin blockers and calcioantagonists in chronic renal failure patients]. ( Calls, I; Gómez Campderá, F; Herrera, J; Liébana, A; Manjón, M; Marco, I; Martínez Fernández, I; Méndez, ML; Morey, A; Ocón, I; Pastors, L; Rincón, B; Robles, NR; Rodríguez Martínez, MA; Rodríguez Villareal, I; Tornero, F; Torrijos, I; Villatoro, J, 2005) |
| " To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO)." | 3.73 | Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. ( Busca, G; Cesana, F; Clari, F; Ferrari, AU; Ferrero, I; Gatti, C; Janetti, MB; Mancia, G; Palladini, G; Perlini, S; Tozzi, R; Vezzoli, M, 2006) |
| "To examine the changes in prescribing of alpha-blockers for hypertension treatment before and after the April 2000 publication of the unfavorable Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) early termination involving the study's doxazosin mesylate arm." | 3.72 | Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. ( Alehegn, T; Cockburn, IM; Finkelstein, SN; Furberg, CD; Ma, J; Stafford, RS, 2004) |
| "There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH)." | 3.72 | [Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension]. ( Aliaga Martínez, L; Fernández-Torres, C; Jiménez-Alonso, J; Mediavilla García, JD; Sabio, JM, 2004) |
| "To compare efficacy and tolerance of tonocardin (doxazosin) and omnik (tamsulosin) in the treatment of benign prostatic hyperplasia (BPH) in hypertensive patients." | 3.72 | [Use of alpha-adrenoblockers in therapy of benign prostatic hyperplasia in patients with arterial hypertension]. ( Mazo, EB; Shashin, MN, 2004) |
| "A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus." | 3.71 | [Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension]. ( Hoogenberg, K; van der Tuin, J, 2002) |
| "To examine the effect of the alpha 1-adrenoblocker tonocardin (doxazosin) on the course of arterial hypertension (AH) and on carbohydrate and lipid metabolism and insulin resistance in patients with type 2 diabetes mellitus (DM) concurrent with AH." | 3.71 | [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension]. ( Balabolkin, MI; Khasanova, ER; Kreminskaia, VM; Trukhina, TV, 2002) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "The aim of the present study was to analyse the nitric oxide (NO)/cyclic GMP (cGMP) relaxing system in spontaneously hypertensive rats of the stroke-prone substrain (SHRSP)." | 3.71 | Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin. ( Casado, S; de Andrés, R; Fortes, J; García-Colis, E; Gomez, J; López-Blaya, A; López-Farré, A; Rico, L; Rodriguez-Feo, JA, 2002) |
| "The goals of this study were to evaluate the tolerability and effectiveness of (1) using doxazosin in the standard and new GITS formulations in adult patients with hypertension who either had uncontrolled or newly diagnosed disease, and (2) replacing standard-formulation doxazosin with doxazosin in the GITS formulation." | 3.71 | A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. ( Anegón, M; Esteban, J; Gil de Miguel, A; Jiménez-García, R; Martínez, J; Sanz de Burgoa, V, 2002) |
| "Valuation of doxazosin, system formulation modified, in the hypertension in the hemodialysis population." | 3.71 | [Doxazosin, of modified liberation, in hemodialyzed patients]. ( Iribar, I; Martínez, I; Montenegro, J; Ocharán-Corcuera, J; Saracho, R, 2002) |
| "Forty-six African patients with essential hypertension aged 40 to 65 years had plasma total cholesterol and triglyceride levels determined at four different periods during a 12-month treatment with doxazosin." | 3.70 | Influence of baseline values. I: Effects on plasma total cholesterol and triglyceride levels during doxazosin treatment for hypertension. ( Agbedana, EO; Ahaneku, JE; Salako, LA; Taylor, GO; Walker, O, 1998) |
| " This report emphasizes the importance of angiotensin II in vascular function alterations induced by aging in SHR." | 3.70 | Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats. ( Cachofeiro, V; Lahera, V; Maeso, R; Navarro-Cid, J; Rodrigo, E; Ruilope, LM, 1999) |
| " With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity." | 3.69 | [Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995) |
| "This study evaluated insulin secretion and insulin sensitivity before and after short-term oral administration of doxazosin in patients with essential hypertension." | 3.69 | Selective alpha 1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension. ( Hakui, N; Kamada, T; Kawamori, R; Sekiya, M; Shiba, Y; Tsujino, T; Yamasaki, Y, 1994) |
| "The objective of the present study was to examine the effects of administration of an alpha 1-adrenoceptor antagonist, doxazosin, for 7 days on cerebral blood flow and the autoregulatory response to hypotension in anesthetized spontaneously hypertensive rats." | 3.69 | The alpha 1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagic hypotension in anesthetized hypertensive rats. ( Cai, H; Fujishima, M; Ibayashi, S; Sadoshima, S; Sugimori, H; Yao, H, 1995) |
| "Fasting blood glucose was determined in 27 adults with essential hypertension at four different periods during a 12-month treatment with doxazosin, an alpha-adrenoceptor antagonist, and in another set of 20 adult hypertensive patients, after 3 months treatment with amlodipine, a calcium antagonist." | 3.69 | Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents. ( Ahaneku, JE, 1996) |
| "The fibrinolytic and metabolic changes associated with doxazosin treatment were evaluated in 20 patients with mild to moderate hypertension." | 3.69 | Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Sheu, WH; Shieh, SM, 1996) |
| "Eleven patients with essential hypertension were studied before and after 3 months' treatment with doxazosin (4-8 mg a day)." | 3.69 | Chronic alpha-1-adrenergic blockade increases sympathoneural but not adrenomedullary activity in patients with essential hypertension. ( Jacobs, MC; Lenders, JW; Thien, T; Willemsen, JJ, 1995) |
| "The aim of the study was to investigate the effect of a new selective alpha 1-adrenoreceptor blocker doxazosin on blood pressure, serum lipids and lipoproteins in patients with essential hypertension." | 3.68 | [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism]. ( Chotkowska, E; Cybulska, I; Galewicz, A; Janaszek-Sitkowska, H; Peczkowska, M; Sawicki, M; Sznajderman, M; Wiernikowska-Wegorek, I, 1993) |
| "Doxazosin, an alpha-adrenergic antagonist with potentially favourable effects on lipid status was evaluated in 25 otherwise healthy general practice patients with mild to moderate hypertension." | 3.68 | Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group. ( , 1992) |
| "The metabolic changes associated with doxazosin treatment of hypertension were evaluated in ten patients with mild hypertension (mean +/- SEM = 150 +/- 3/100 +/- 1 mm Hg) and a plasma triglyceride (TG) concentration > 1." | 3.68 | Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. ( Chen, YD; Fuh, MM; Reaven, GM; Shen, DC; Sheu, WH; Shieh, SM, 1992) |
| " Doxazosin, a new selective alpha 1-inhibitor used in the treatment of hypertension, is compared with the established beta-blocker, atenolol." | 3.68 | The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden. ( Lindgren, B, 1990) |
| " The pharmacokinetics of doxazosin, following a single oral dose (1 mg) and chronic oral dosing (doubling doses up to a maximum of 16 mg day-1), were studied in 18 patients with mild to moderate hypertension and stable renal function varying from normal to severely impaired." | 3.68 | The pharmacokinetics of doxazosin in patients with hypertension and renal impairment. ( Dewhurst, AG; Honeywell, R; Oliver, RM; Renwick, AG; Upward, JW; Waller, DG, 1990) |
| "A single dose of doxazosin, a long-acting postsynaptic alpha 1-adrenoceptor antagonist, was administered to seven patients with essential hypertension." | 3.67 | Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. ( Kaneko, Y; Miyajima, E; Miyakawa, T; Shionoiri, H; Takagi, N; Umemura, S; Yasuda, G; Yoshimura, H, 1987) |
| "Since it is not known for certain which alpha-adrenergic receptors mediate renal vasoconstriction in human essential hypertension, we infused either doxazosin (n = 7) or yohimbine (n = 7) into the renal arteries of hypertensive subjects immediately prior to diagnostic angiography." | 3.67 | Role of alpha 1- and alpha 2-adrenergic receptors in the human hypertensive kidney. ( Birkenhäger, WH; de Bos, R; de Leeuw, PW; van Es, PN, 1987) |
| "Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension." | 3.67 | Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988) |
| "The antihypertensive efficacy, lipid effects, and safety of doxazosin, a selective alpha 1-inhibitor for the reduction of coronary heart disease (CHD) risk in hypertensive patients, was assessed in a general medical practice setting." | 3.67 | Clinical experience with doxazosin in general medical practice. ( Rosenthal, J, 1988) |
| "Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension." | 3.67 | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988) |
| "The acute and chronic haemodynamic effects of doxazosin were studied in 14 patients (10 males, four females) with essential hypertension, at rest supine and sitting and during 100 W bicycling exercise." | 3.67 | Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. ( Haugland, H; Lund-Johansen, P; Omvik, P, 1986) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| " Orthostatic hypotension is a concern with the use of α1-blockers especially in the elderly, and requires careful initial bedtime dosing and avoiding overdosing." | 2.82 | Role of α1-blockers in the current management of hypertension. ( Buranakitjaroen, P; Cheng, HM; Chia, YC; Kario, K; Li, H; Li, Y; Sogunuru, GP; Tay, JC; Van Huynh, M; Wang, JG; Wang, TD; Xu, TY, 2022) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 2.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
| "As combination therapy for the treatment of hypertension, Ca channel blockers (CCBs), angiotensin II (AII) receptor blockers (ARBs), and/or AII-converting enzyme (ACE) inhibitors are mainly prescribed, while the efficacy of alpha(1)-blockers in such combination therapy remains unknown." | 2.73 | Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. ( Eto, K; Ohta, Y; Onaka, U; Tsuchihashi, T; Ueno, M, 2007) |
| "Doxazosin GITS was increased to 8 mg/d after 2 or 4 weeks if patients did not respond (sitting blood pressure <140/90 mm Hg and 10/10-mm Hg decrease from baseline)." | 2.72 | Controlled-release doxazosin as combination therapy in hypertension: the GATES study. ( Black, HR; Bullen, K; Keck, M; Koren, A; Meredith, P; Quinn, S, 2006) |
| " DOX GITS dosage remained unchanged at 4 mg throughout the study." | 2.72 | Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure. ( Os, I, 2006) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "Nitrites/nitrates were significantly lower (P < 0." | 2.72 | Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, R; Galli, S; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Salvadeo, S; Tinelli, C, 2006) |
| "Chlorthalidone was at least equivalent to amlodipine and lisinopril in all of the outcomes measured, and was better in some, notably heart failure." | 2.71 | The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure. ( Vidt, DG, 2003) |
| " A total of 154 patients suffered adverse events (AE), 127 during phase I and 27 in phase II." | 2.71 | Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients. ( Anegón, M; Apaolaza, I; Carrasco, P; Esteban, J; Gil, A; Jiménez-García, R, 2003) |
| " Laboratory tests were performed, adverse events recorded, and prostatic symptomatology examined." | 2.71 | Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg. ( Hurtado, S; Lloveras, J; Oliveras, A; Puig, JM; Vázquez, S, 2003) |
| "Doxazosin GITS is a safe agent which can reduce cardiovascular risk." | 2.71 | Doxazosin GITS trough to peak ratio and 24-hour blood pressure monitoring in the management of hypertension in renal transplant patients. ( Grinyó, JM; Ibernón, M; Martínez Castelao, A; Moreso, F; Rama, I; Sanz, V; Sarrias, X, 2003) |
| "Doxazosin has a neutral effect on both peripheral and hepatic insulin action, but improves endothelium-dependent vasodilation." | 2.71 | Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. ( Atkinson, AB; Bassett, J; Bell, PM; Courtney, CH; Ennis, CN; McCance, DR; Sheridan, B, 2003) |
| " Bedtime dosing with doxazosin GITS, however, significantly reduced BP throughout the 24h both when used as a monotherapy and when used in combination with other antihypertensive pharmacotherapy." | 2.71 | Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. ( Ayala, DE; Calvo, C; Covelo, M; Domínguez, MJ; Fernández, JR; Fontao, MJ; Hermida, RC; López, JE, 2004) |
| "Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients." | 2.71 | Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. ( Chung, BH; Hong, SJ; Lee, MS, 2005) |
| "CARDIOVASCULAR RISK OF LEFT VENTRICULAR HYPERTROPHY: Because of the rhythmic, mechanical and ischemic risk related to it, the left ventricular hypertrophy (LVH) is considered to be a major independent risk factor for cardiovascular disease which should be screened for and treated early." | 2.70 | [Management of hypertensive patients with left ventricular hypertrophy]. ( Ambrosioni, E, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 2.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "Moreover, reactive hyperemia evaluated by strain-gauge plethysmography after 6 months (1." | 2.70 | Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. ( Higaki, J; Jinno, T; Katsuya, T; Komai, N; Matsumoto, K; Moriguchi, A; Ogihara, T; Ohishi, M; Rakugi, H; Yanagitani, Y, 2002) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 2.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| " We studied the effect of nighttime dosing of an alpha(1)-adrenergic blocker, doxazosin, on the BP dipping status of 118 hypertensives, all of whom underwent 24-hour ambulatory BP monitoring before and after treatment." | 2.69 | Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin : results from the HALT study. ( Kario, K; Pickering, TG; Schwartz, JE, 2000) |
| "A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study." | 2.68 | Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. ( Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995) |
| " After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks." | 2.68 | [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. ( Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995) |
| " Terazosin, an alpha 1-adrenergic blocking agent, was given initially at the dosage of 1 mg daily." | 2.68 | Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. ( Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R, 1996) |
| "Both doxazosin and HCTZ were effective drugs over 1 year for treating hypertension." | 2.68 | Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. ( Flack, JM; Gonzalez, NM; Grimm, RH; Liebson, PR; Schoenberger, JA, 1996) |
| "Doxazosin was given in doses of 1 mg per day initially, then increased weekly to 2, 4, 8, and 16 mg, until goal blood pressure or maximum dose was reached or side effects limited further increase." | 2.68 | Neural mechanisms in primary hypertension. Efficacy of alpha-blockade with doxazosin during stress. ( DeQuattro, V; Lee, D; Lu, ZW, 1996) |
| "Doxazosin therapy was characterized by significant increase in the levels of mean plasma total protein and albumin, while moduretic therapy showed significant reduction in the mean values of plasma creatinine and calcium." | 2.68 | Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. ( Agbedana, EO; Ahaneku, JE; Salako, LA; Sowunmi, A; Taylor, GO; Walker, O, 1996) |
| "Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin." | 2.68 | Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment. ( Canessa, ML; Castellino, P; DeFronzo, RA; Giordano, M; Solini, A, 1997) |
| "Essential hypertension is characterized by an insulin-resistance state that may be responsible for the increased atherogenesis typical of this disease." | 2.67 | Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. ( Appendino, M; Giorda, C, 1993) |
| "Hypertension and hypercholesterolemia are frequently associated with this leading to considerable cardiovascular risk." | 2.67 | [Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme]. ( Alcázar de la Osa, JM; Fernández Pinilla, C; Luque Otero, M; Martell Claros, N; Rodicio Díaz, JL; Ruilope Urioste, LM, 1993) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 2.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| " Doxazosin produced rightward shifts of the PE pressor dose-response curves but had no effect on responses to AII." | 2.67 | Vascular pressor responses in treated and untreated essential hypertension. ( Donnelly, R; Elliott, HL; Howie, CA; Reid, JL; Sumner, DJ, 1990) |
| "Both doxazosin and prazosin were well tolerated; seven patients (5." | 2.67 | A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension. ( Fukiyama, K; Iimura, O; Ijichi, H; Inagaki, Y; Ishii, M; Kaneko, Y; Omae, T; Yagi, S; Yamada, K; Yoshinaga, K, 1991) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 2.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "With doxazosin treatment, the mean supine and standing SBPs were reduced by 15 mmHg and 13 mmHg, respectively." | 2.67 | An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency. ( Anderton, JL; Notghi, A, 1990) |
| " Starting at one mg, dosage was doubled every 2 weeks during a 10-week treatment period to a maximum dose of 16 mg once daily." | 2.66 | Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins. ( Ames, RP; Kiyasu, JY, 1989) |
| "Because coronary heart disease is known to have many causes, primary preventive therapy must logically go beyond the relatively simple goal of lowering blood pressure." | 2.66 | Effects of oral antihypertensive agents on blood lipid levels. ( Leren, P, 1986) |
| " Another multicenter trial reported that doxazosin therapy was effective at low doses; 76% of those responders achieved controlled blood pressure at a mean dosage of 3." | 2.66 | Efficacy and safety of doxazosin in hypertension therapy. ( Hayduk, K, 1987) |
| " Patients were then maintained for another 4 weeks on the dosage necessary to control diastolic BP to less than or equal to 90 mm Hg (phase 3)." | 2.66 | A multicenter trial of doxazosin in West Germany. ( Rosenthal, J, 1987) |
| "Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension." | 2.66 | Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. ( Pool, JL, 1987) |
| "Doxazosin is a competitive inhibitor of norepinephrine at alpha 1 adrenoceptors on vascular smooth muscle, where it blocks vasoconstriction." | 2.66 | Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension. ( Wilner, KD; Ziegler, MG, 1987) |
| "Doxazosin is an effective hypotensive agent with beneficial effects on serum lipid levels." | 2.66 | A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. ( Black, H; Nash, DT; Reeves, RL; Schonfeld, G; Weidler, DJ, 1987) |
| "Doxazosin is an effective, well-tolerated, once-daily antihypertensive agent; it is comparable with terazosin but at a lower daily dosage." | 2.66 | Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. ( Hayduk, K; Schneider, HT, 1987) |
| "Doxazosin monotherapy was effective in eight of 12 patients (66." | 2.66 | Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. ( Miura, Y; Yoshinaga, K, 1988) |
| "Doxazosin is a new quinazoline derivative that, like prazosin, has selectivity for alpha 1-receptors." | 2.66 | Clinical pharmacology of doxazosin in patients with essential hypertension. ( Caplan, N; Cubeddu, LX; Ferry, D; Fuenmayor, N, 1987) |
| " The plasma elimination half-life during the dose interval in these patients was 16." | 2.66 | A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients. ( Hosie, J; Scott, MG; Scott, PJ, 1988) |
| "The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients." | 2.66 | Doxazosin in patients with hypertension. ( Conrad, KA; Fagan, TC; Falkner, FC; Lazar, JD; Lee, S; Mackie, MJ; Mayshar, PV; Souhrada, JF, 1988) |
| "The prevalence of benign prostatic hypertrophy (BPH) and erectile dysfunction (ED) both increase with age, and increasing evidence suggests a common cause rather than independent age-related changes." | 2.43 | Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. ( DE Rose, AF; Kaplan, SA; Kirby, RS; McVary, KT; O'leary, MP, 2006) |
| "The prevalence of both benign prostatic hyperplasia (BPH) and hypertension increases with advancing age." | 2.41 | The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both. ( Flack, JM, 2002) |
| "Doxazosin has been shown to be effective in reducing the symptoms of BPH in elderly patients whose blood pressure is well controlled by concomitant antihypertensive medication." | 2.41 | Doxazosin in elderly patients with hypertension. ( Fawzy, A; Weinberger, MH, 2000) |
| " It should be stated that the described pharmacological differences of doxazosine GITS in younger and elderly, in female and male patients do not influence significantly initial dosing of the drug." | 2.41 | [Cardura XL--a unique drug formulation--doxazosine administered in a slow-release form (doxazosine GITS)]. ( Grzeszczak, W, 2000) |
| "The drugs used to treat hypertension may cause ED." | 2.41 | The treatment of hypertension in patients with erectile dysfunction. ( Khan, MA; Mikhailidis, DP; Milionis, HJ; Morgan, RJ, 2000) |
| "Doxazosin is a long-acting alpha 1-adrenoceptor antagonist structurally related to prazosin and terazosin." | 2.39 | Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. ( Fulton, B; Sorkin, EM; Wagstaff, AJ, 1995) |
| "Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment." | 2.39 | Profile of doxazosin in patients with benign prostatic hyperplasia. ( Janknegt, RA, 1995) |
| "Doxazosin appears to inhibit the development of CHD on two fronts." | 2.38 | Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. ( Pool, JL, 1991) |
| "Doxazosin therapy was associated with a trend toward correcting the disturbances of lipoprotein metabolism characteristic of NIDDM." | 2.38 | Doxazosin therapy in the treatment of diabetic hypertension. ( Feher, MD, 1991) |
| " It is readily absorbed, with high bioavailability and a relatively long plasma half-life, neither of which property is influenced by age." | 2.38 | Clinical pharmacotherapeutics of doxazosin. ( Taylor, SH, 1989) |
| "The drug treatment of mild hypertension has been shown to afford protection against fatal and nonfatal strokes, congestive heart failure, progression to more severe levels of hypertension, and all-cause mortality, but not against the complications of coronary artery disease." | 2.38 | Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension. ( Davey, MJ, 1989) |
| "Control of high blood pressure has failed to reduce the risk of atherosclerotic coronary heart disease (CHD)." | 2.38 | Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. ( Nelson, EB; Pool, JL; Taylor, AA, 1989) |
| "Clonidine is a centrally acting alpha 2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day." | 2.37 | Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. ( Anavekar, SN; Conway, EL; Drummer, OH; Howes, LG; Jarrott, B; Louis, WJ; McNeil, JJ; Workman, B, 1987) |
| "As a surgical treatment of pheochromocytomas, laparoscopic adrenalectomy is an effective and safe approach, in selected cases even for PCCs >6 cm in diameter, although patients with such large tumors may have a higher conversion rate and more intraoperative hypertensive crises." | 1.39 | Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series. ( Colantuoni, V; Conzo, G; Corcione, F; De Palma, M; Ferraro, F; Milone, M; Musella, M; Napolitano, S; Palazzo, A; Pasquali, D; Santini, L; Sinisi, AA, 2013) |
| "Doxazosin GITS treatment resulted in optimal management of BP within the normal range, especially in pharmacologically or physiologically hypertensive patients." | 1.36 | Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. ( Chung, BH; Lee, SH; Mah, SY; Park, KK, 2010) |
| "Doxazosin was usually added as the fifth antihypertensive drug in individuals who were either unresponsive to or intolerant of the combination of other antihypertensives." | 1.35 | Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. ( Ceral, J; Solar, M, 2009) |
| "A 29-year-old man had been treated for hypertension for 10 years." | 1.35 | [Ejaculatory disorder caused by doxazosin administration for blood pressure control in patient with pheochomocytoma]. ( Amano, T; Imao, T; Takemae, K; Yamauchi, K, 2009) |
| "The patient demonstrated marked orthostatic hypotension without increment of heart rate, increased variability of blood pressure and abnormal hypertensive surges in a single 24 hour period, and abnormal response of heart rate during Valsalva's maneuver." | 1.34 | [Case of baroreflex failure after bilateral revascularization of the cervical carotid artery]. ( Azuma, Y; Imai, K; Makino, M; Niwa, F; Oda, K; Oshima, F, 2007) |
| "To assess the renal benefits of combined angiotensin-converting enzyme inhibition and alpha(1)-adrenergic antagonism, we studied the antihypertensive and renoprotective effects of temocapril (TMP) alone and in combination with doxazosin (DOX) in spontaneously hypertensive rats (SHR)/Izumo rats with renal ablation." | 1.32 | Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation. ( Abe, K; Ito, O; Kanazawa, M; Kohzuki, M; Kurosawa, H; Minami, N; Saito, T; Yasujima, M, 2004) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 1.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| "Doxazosin treatment reduced the formation of Bax-Bcl-2 complexes in the left ventricle of SHRs, and this was accompanied by a decrease in the levels of 85kDa PARP and a reduction in apoptotic left ventricular cells." | 1.31 | Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats. ( Aceituno, E; Ayala, R; Casado, S; Castilla, C; Farré, J; Fortes, J; García-Durán, M; González-Fernández, F; López-Farré, A; Rico, L; Rodríguez-Feo, JA, 2000) |
| "Doxazosin is a long acting alpha(1)-adrenoceptor antagonist, used in the treatment of essential hypertension and/or benign prostatic hyperplasia (BPH)." | 1.31 | Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. ( Jagroop, IA; Mikhailidis, DP, 2001) |
| "Doxazosin is a cost-effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy." | 1.31 | The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. ( Arikian, S; Bustacchini, S; Casciano, J; Casciano, R; Doyle, J; Kim, R; Kopp, Z; Marchant, N, 2001) |
| " Among the 8 subjects in whom doxazosin dosage was increased to the maximum of 4 mg, the mean blood pressure achieved at 4 mg did not differ from that achieved at 2 mg (136/87 v 136/88 mm Hg)." | 1.31 | Low-dose alpha/beta blockade in the treatment of essential hypertension. ( Gerber, LM; Mann, SJ, 2001) |
| "Doxazosin treatment prevented impaired vasodilatory response to SNP." | 1.31 | [Doxazosin and soluble guanylate cyclase in a rat model of hypertension]. ( Cabestrero, F; Casado, S; de Andrés, R; Farré, J; Fortes, J; Gómez, J; López-Farré, A; Núñez, A; Rico, L; Rodríguez-Feo, JA, 2001) |
| "In this study, 15 patients with chronic renal failure were treated only with doxazosin and diuretics for 6 months and their blood pressure, renal parameters and lipid profile were measured." | 1.31 | Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. ( Amano, K; Fujiyama, S; Hasegawa, T; Iba, O; Iwasaka, T; Kosaki, A; Masaki, H; Matsubara, H; Mori, Y; Nose, A; Okigaki, M; Shibasaki, Y; Tanaka-Uchiyama, Y; Tateishi, E, 2001) |
| "Doxazosin (2 to 4 mg) was administered alone or with other previously received antihypertensive drugs for 6 months." | 1.31 | Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. ( Adachi, M; Hirano, T; Kashiwazaki, K; Yoshino, G, 2001) |
| "Doxazosin treatment prevented the impairment in endothelium-dependent vascular relaxation in the high cholesterol/antioxidant-deficient group." | 1.30 | Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. ( Coffee, K; Guerra, J; Hayakawa, H; Raij, L, 1997) |
| "Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0." | 1.30 | Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. ( Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998) |
| "Doxazosin is an antihypertensive drug that gives rise to 6- and 7-hydroxydoxazosin during hepatic metabolism." | 1.30 | Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies. ( Arnstad, JE; Brude, IR; Drevon, CA; Nenseter, MS; Valnes, KN; Viken, K, 1999) |
| "Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors." | 1.29 | Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. ( Kirby, RS, 1994) |
| " However, in a previous study we established that chronic administration of the selective alpha 1-adrenoceptor antagonist terazosin to SHR failed to prevent this phenomenon." | 1.29 | Influence of alpha 1- and alpha 2-adrenoceptor antagonist therapy on the development of hypertension in spontaneously hypertensive rats. ( Frewin, DB; Head, RJ; Jonsson, JR; Mano, MT; Young, RL, 1993) |
| "Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 1.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 1.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "After hypertension was controlled with doxazosin (a long-acting alpha 1 adrenergic blocker), her cardiac function gradually improved." | 1.29 | Severe hypertension and cardiac failure associated with neuroblastoma: a case report. ( Akiba, K; Hayasaka, K; Katsuura, M; Obata, K; Otaki, S; Sato, S; Sendo, D; Tanabe, S; Wakabayashi, T; Yamagiwa, I; Yokoyama, S, 1996) |
| "In previously untreated rats, pretreatment with enalaprilat shifted the dose-response curve for the hypotensive effect of doxazosin to the left, indicating synergism." | 1.28 | A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats. ( Marwood, JF; Stokes, GS; Tierney, G, 1992) |
| " Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)." | 1.28 | Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. ( Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992) |
| " After one dosage with a directly acting venodilator (nitroglycerin 5 mg s." | 1.28 | Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis. ( Draaijer, P; Gladziwa, U; Kooman, JP; Leunissen, KM; Peltenburg, HG; Struyker-Boudier, HA; van Bortel, LM; van Hooff, JP; Wijnen, JA, 1992) |
| " The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved." | 1.28 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992) |
| "Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be a suitable agent for treating these patients." | 1.28 | [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension]. ( Brusletto, B; Daae, LN; Holme, I; Kierulf, P; Syvertsen, JO; Westheim, A, 1991) |
| "Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be suitable for treating these patients." | 1.28 | Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects. ( Brusletto, B; Daae, LN; Holme, I; Kierulf, P; Syvertsen, JO; Westheim, A, 1990) |
| "Doxazosin is a postsynaptic alpha-1 adrenoceptor blocker suitable for once a day treatment regime." | 1.28 | [Doxazosin for the treatment of arterial hypertension]. ( Buzzaccarini, F; Casolino, P; Giusto, M; Mozzato, MG; Pessina, AC; Rubino, N; Semplicini, A; Serena, L; Valle, R, 1990) |
| " The elimination half-life in plasma was 10." | 1.28 | Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects. ( Conway, EL; Drummer, OH; Howes, LG; Louis, WJ; McNeil, JJ; Meng, L; Raymond, K, 1989) |
| " This doxazosin dosage reduced the diastolic blood pressure on average from 103 to 91 mmHg (P = 0." | 1.28 | Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. ( Biernacki, W; Flenley, DC, 1989) |
| "Doxazosin was administered either short-term (20 or 200 mg/kg/day by gavage over 5 days) or long-term (0." | 1.27 | Effects of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat. ( Chichester, CO; Rodgers, RL, 1987) |
| "Prazosin is a quinazoline derivative, which lowers blood pressure by selective alpha-1-receptor antagonism." | 1.27 | Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists. ( Reid, JL; Vincent, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 69 (14.65) | 18.7374 |
| 1990's | 171 (36.31) | 18.2507 |
| 2000's | 179 (38.00) | 29.6817 |
| 2010's | 44 (9.34) | 24.3611 |
| 2020's | 8 (1.70) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, SF | 1 |
| Davey, MJ | 2 |
| Hardstone, JD | 1 |
| Lewis, BN | 1 |
| Palmer, MJ | 1 |
| Veldhuizen, GP | 1 |
| Alnazer, RM | 1 |
| de Leeuw, PW | 6 |
| Kroon, AA | 1 |
| Meremo, A | 1 |
| Paget, G | 1 |
| Duarte, R | 1 |
| Dickens, C | 1 |
| Dix-Peek, T | 1 |
| Bintabara, D | 1 |
| Naicker, S | 1 |
| Mansbart, F | 1 |
| Kienberger, G | 1 |
| Sönnichsen, A | 1 |
| Mann, E | 1 |
| Li, H | 1 |
| Xu, TY | 1 |
| Li, Y | 1 |
| Chia, YC | 1 |
| Buranakitjaroen, P | 1 |
| Cheng, HM | 1 |
| Van Huynh, M | 1 |
| Sogunuru, GP | 1 |
| Tay, JC | 1 |
| Wang, TD | 1 |
| Kario, K | 14 |
| Wang, JG | 2 |
| Hohl, M | 1 |
| Lauder, L | 1 |
| Sevimli, Ö | 1 |
| Tokcan, M | 1 |
| Wagmann, L | 1 |
| Götzinger, F | 1 |
| Schneider, C | 1 |
| Hübner, U | 1 |
| Lehnert, U | 1 |
| Meyer, MR | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Ohyama, K | 1 |
| Hori, Y | 1 |
| Sugiura, M | 1 |
| Doumas, M | 2 |
| Imprialos, KP | 1 |
| Kallistratos, MS | 1 |
| Manolis, AJ | 1 |
| Pigot, JE | 1 |
| Szeto, MCH | 1 |
| Iglesias, P | 1 |
| Santacruz, E | 1 |
| García-Sancho, P | 1 |
| Marengo, AP | 1 |
| Guerrero-Pérez, F | 1 |
| Pian, H | 1 |
| Fajardo, C | 1 |
| Villabona, C | 2 |
| Díez, JJ | 1 |
| Yoshida, T | 1 |
| Kuwabara, M | 1 |
| Hoshide, S | 10 |
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 5 |
| Davis, BR | 15 |
| Pressel, SL | 2 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Turgeon, R | 1 |
| Garrison, S | 1 |
| Allan, GM | 1 |
| Foster, S | 1 |
| Foster, R | 1 |
| Jackson, P | 1 |
| Song, S | 1 |
| MacDonald, TM | 4 |
| Williams, B | 6 |
| Webb, DJ | 3 |
| Morant, S | 3 |
| Caulfield, M | 1 |
| Cruickshank, JK | 4 |
| Ford, I | 3 |
| Sever, P | 3 |
| Mackenzie, IS | 2 |
| Padmanabhan, S | 3 |
| McCann, GP | 1 |
| Salsbury, J | 3 |
| McInnes, G | 2 |
| Brown, MJ | 8 |
| Ekholm, M | 1 |
| Jekell, A | 3 |
| Wallén, NH | 1 |
| Gigante, B | 1 |
| Kahan, T | 3 |
| Morant, SV | 2 |
| McInnes, GT | 1 |
| Caulfield, MJ | 2 |
| Hernández-Montoliu, L | 1 |
| Simó-Servat, A | 1 |
| Kalani, M | 2 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Jiang, B | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Johnson, K | 1 |
| Oparil, S | 1 |
| Tereshchenko, LG | 1 |
| Stojkov, NJ | 1 |
| Janjic, MM | 1 |
| Kostic, TS | 1 |
| Andric, SA | 1 |
| Radchenko, GD | 1 |
| Sirenko, YM | 1 |
| Kushnir, SM | 1 |
| Torbas, OO | 1 |
| Dobrokhod, AS | 1 |
| Conzo, G | 2 |
| Musella, M | 2 |
| Corcione, F | 2 |
| Depalma, M | 1 |
| Stanzione, F | 1 |
| Della-Pietra, C | 1 |
| Palazzo, A | 2 |
| Napolitano, S | 2 |
| Pasquali, D | 2 |
| Milone, M | 2 |
| Agostino-Sinisi, A | 1 |
| Ferraro, F | 2 |
| Santini, L | 2 |
| Wolak, T | 1 |
| Toledano, R | 1 |
| Novack, V | 1 |
| Sharon, A | 1 |
| Shalev, A | 1 |
| Wolak, A | 1 |
| Yasuda, G | 3 |
| Saka, S | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Sternlicht, H | 1 |
| Bakris, GL | 1 |
| Mackenzie, I | 1 |
| Huynh, K | 1 |
| Widimský, J | 2 |
| Rosenberg, M | 1 |
| Stephens, E | 1 |
| Divisón Garrote, JA | 1 |
| Escobar Cervantes, C | 1 |
| Boutari, C | 1 |
| Stavropoulos, K | 1 |
| Imprialos, K | 1 |
| Karagiannis, A | 1 |
| Gkaliagkousi, E | 1 |
| Gavriilaki, E | 1 |
| Triantafyllou, A | 1 |
| Douma, S | 1 |
| Dale, A | 1 |
| Hartley, P | 1 |
| Goldacre, B | 1 |
| Kaysin, A | 1 |
| Mounsey, A | 1 |
| Matsui, Y | 8 |
| Eguchi, K | 9 |
| Shibasaki, S | 7 |
| Ishikawa, J | 8 |
| Pickering, TG | 10 |
| Shimada, K | 9 |
| Chapman, N | 2 |
| Chang, CL | 1 |
| Dahlöf, B | 1 |
| Sever, PS | 2 |
| Wedel, H | 1 |
| Poulter, NR | 1 |
| Il'nitskiĭ, AN | 1 |
| Proshchaev, KI | 1 |
| Filippov, SR | 1 |
| Liutsko, VV | 1 |
| Slikin, VV | 1 |
| Hua, CX | 1 |
| Hua, L | 1 |
| Li, N | 1 |
| Wang, L | 1 |
| Pang, HM | 1 |
| Ming, GH | 1 |
| Huang, Y | 1 |
| Cheng, XR | 1 |
| Liu, H | 1 |
| Wu, Y | 1 |
| Xu, L | 1 |
| Kang, J | 1 |
| Xu, ZM | 1 |
| Li, YS | 1 |
| Ishikawa, S | 4 |
| Kabutoya, T | 4 |
| Schwartz, JE | 3 |
| Kostis, JB | 1 |
| Simpson, LM | 3 |
| Black, HR | 6 |
| Cushman, WC | 3 |
| Einhorn, PT | 5 |
| Farber, MA | 2 |
| Ford, CE | 7 |
| Levy, D | 3 |
| Massie, BM | 3 |
| Nawaz, S | 1 |
| Yano, Y | 1 |
| Barrios, V | 3 |
| Escobar, C | 3 |
| Tomás, JP | 2 |
| Calderon, A | 2 |
| Echarri, R | 2 |
| Rodilla, E | 1 |
| Costa, JA | 1 |
| Pérez-Lahiguera, F | 1 |
| Baldó, E | 1 |
| González, C | 1 |
| Pascual, JM | 1 |
| Gallego-Delgado, J | 1 |
| Connolly, SB | 1 |
| Lázaro, A | 1 |
| Sadlier, D | 1 |
| Kieran, NE | 1 |
| Sugrue, DD | 1 |
| Doran, P | 1 |
| Brady, HR | 1 |
| Osende, J | 1 |
| Egido, J | 1 |
| Ceral, J | 1 |
| Solar, M | 1 |
| Solà, R | 1 |
| Boj, M | 1 |
| Hernandez-Flix, S | 1 |
| Camprubí, M | 1 |
| Yono, M | 2 |
| Yoshida, M | 2 |
| Yamamoto, Y | 2 |
| Imanishi, A | 2 |
| Fukagawa, A | 2 |
| Latifpour, J | 2 |
| Eto, M | 2 |
| Amano, T | 1 |
| Imao, T | 1 |
| Takemae, K | 1 |
| Yamauchi, K | 1 |
| Usuda, K | 1 |
| Katayama, Y | 1 |
| Spoladore, R | 1 |
| Roccaforte, R | 1 |
| Fragasso, G | 1 |
| Gardini, C | 1 |
| Palloshi, A | 1 |
| Cuko, A | 1 |
| Arioli, F | 1 |
| Salerno, A | 1 |
| Margonato, A | 1 |
| Grimm, RH | 5 |
| Piller, LB | 5 |
| Cutler, JA | 4 |
| Margolis, KL | 3 |
| Barzilay, J | 2 |
| Dart, RA | 1 |
| Graumlich, JF | 1 |
| Murden, RA | 1 |
| Randall, OS | 2 |
| Haywood, LJ | 2 |
| Crow, RS | 1 |
| Williard, A | 1 |
| Ganesh, HK | 1 |
| Acharya, SV | 1 |
| Goerge, J | 1 |
| Bandgar, TR | 1 |
| Menon, PS | 1 |
| Shah, NS | 1 |
| Zou, D | 1 |
| Grote, L | 1 |
| Eder, DN | 1 |
| Radlinski, J | 1 |
| Hedner, J | 1 |
| Chen, CY | 1 |
| Fujita, T | 1 |
| Hobbs, FD | 1 |
| Kim, SJ | 1 |
| Staessen, JA | 1 |
| Tanomsup, S | 1 |
| Lee, SH | 1 |
| Park, KK | 1 |
| Mah, SY | 1 |
| Chung, BH | 3 |
| Gonokami, K | 1 |
| Obara, T | 1 |
| Kobayashi, M | 1 |
| Katada, S | 1 |
| Hara, A | 1 |
| Metoki, H | 1 |
| Asayama, K | 1 |
| Kikuya, M | 1 |
| Ohkubo, T | 1 |
| Imai, Y | 1 |
| Chytil, L | 1 |
| Strauch, B | 1 |
| Cvačka, J | 1 |
| Marešová, V | 1 |
| Holaj, R | 1 |
| Slanař, O | 1 |
| Chatziralli, IP | 1 |
| Sergentanis, TN | 1 |
| Scholten, A | 1 |
| Vriens, MR | 1 |
| Cromheecke, GJ | 1 |
| Borel Rinkes, IH | 1 |
| Valk, GD | 1 |
| Parati, G | 2 |
| Shibazaki, S | 1 |
| Lynch, AI | 2 |
| Eckfeldt, JH | 3 |
| Boerwinkle, E | 3 |
| Leiendecker-Foster, C | 3 |
| Arnett, DK | 3 |
| Groeben, H | 1 |
| Hamada, N | 1 |
| Nishi, Y | 1 |
| Tajiri, Y | 1 |
| Setoyama, K | 1 |
| Kamimura, R | 1 |
| Miyahara, K | 1 |
| Nuruki, N | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Kojima, M | 1 |
| Mifune, H | 1 |
| De Palma, M | 1 |
| Sinisi, AA | 1 |
| Colantuoni, V | 1 |
| Wright, JT | 4 |
| Felicetta, JV | 1 |
| Stokes, JD | 1 |
| Paran, E | 1 |
| Flack, JM | 4 |
| Ambrosioni, E | 1 |
| Cybulski, J | 1 |
| Ceremuzyński, L | 1 |
| Bratteli, CW | 1 |
| Glasser, SP | 1 |
| Gurevich, MA | 1 |
| Hoogenberg, K | 1 |
| van der Tuin, J | 1 |
| Mulatero, P | 1 |
| Rabbia, F | 1 |
| Milan, A | 1 |
| Paglieri, C | 1 |
| Morello, F | 1 |
| Chiandussi, L | 1 |
| Veglio, F | 1 |
| Varani, K | 2 |
| Manfredini, R | 2 |
| Iannotta, V | 1 |
| Pancaldi, C | 1 |
| Cattabriga, E | 1 |
| Uluoglu, C | 1 |
| Borea, PA | 2 |
| Portaluppi, F | 2 |
| Düsing, R | 1 |
| Hoogerbrugge, N | 1 |
| de Groot, E | 1 |
| de Heide, LH | 1 |
| de Ridder, MA | 1 |
| Birkenhägeri, JC | 1 |
| Stijnen, T | 1 |
| Jansen, H | 1 |
| Janssen, CA | 1 |
| Balabolkin, MI | 1 |
| Khasanova, ER | 1 |
| Trukhina, TV | 1 |
| Kreminskaia, VM | 1 |
| Wepner, U | 1 |
| Vidt, DG | 2 |
| Slany, J | 1 |
| Ukhal', MI | 1 |
| Strashnyĭ, VV | 1 |
| Ukhal', GM | 1 |
| Shumilin, MV | 1 |
| Jiménez-García, R | 2 |
| Anegón, M | 2 |
| Esteban, J | 2 |
| Carrasco, P | 1 |
| Apaolaza, I | 1 |
| Gil, A | 1 |
| Lund-Johansen, P | 4 |
| Kirby, RS | 6 |
| Boesen, EI | 1 |
| Lewis, TV | 1 |
| Kett, MM | 1 |
| Anderson, WP | 1 |
| Lemmer, B | 1 |
| Nold, G | 1 |
| Diener, HC | 1 |
| Oliveras, A | 1 |
| Hurtado, S | 1 |
| Vázquez, S | 1 |
| Puig, JM | 1 |
| Lloveras, J | 1 |
| Martínez Castelao, A | 1 |
| Ibernón, M | 1 |
| Sarrias, X | 1 |
| Sanz, V | 2 |
| Moreso, F | 1 |
| Rama, I | 1 |
| Grinyó, JM | 2 |
| Courtney, CH | 1 |
| McCance, DR | 1 |
| Atkinson, AB | 1 |
| Bassett, J | 1 |
| Ennis, CN | 1 |
| Sheridan, B | 1 |
| Bell, PM | 1 |
| Labiós, M | 3 |
| Martínez, M | 3 |
| Gabriel, F | 3 |
| Gómez-Biedma, S | 1 |
| Guiral, V | 3 |
| Vivó, M | 1 |
| Aznar, J | 3 |
| Ueshiba, H | 1 |
| Miyachi, Y | 1 |
| Khlynova, OV | 1 |
| Tuev, AV | 1 |
| Agafonov, AV | 1 |
| Shkliaeva, LN | 1 |
| Fujimoto, S | 1 |
| Mizuno, R | 1 |
| Saito, Y | 1 |
| Nakamura, S | 1 |
| Tepliakov, AT | 1 |
| Gavrilova, NV | 1 |
| Garganeeva, AA | 1 |
| Stafford, RS | 1 |
| Finkelstein, SN | 1 |
| Cockburn, IM | 1 |
| Alehegn, T | 1 |
| Ma, J | 1 |
| Abe, M | 1 |
| Mori, K | 1 |
| Nagai, K | 1 |
| Ito, S | 1 |
| Lohm, L | 1 |
| Lindh, E | 1 |
| Frösing, R | 1 |
| Sauerbrey-Wullkopf, N | 1 |
| Leverkus, F | 1 |
| Järhult, B | 1 |
| Lindahl, SO | 1 |
| Furberg, C | 2 |
| Campo, C | 1 |
| Segura, J | 1 |
| Roldán, C | 1 |
| Alcázar, JM | 1 |
| Rodicio, JL | 1 |
| Ruilope, LM | 2 |
| Nilsson, PM | 1 |
| Gustafsson, LL | 1 |
| Lujan, M | 1 |
| Ferruelo, A | 1 |
| Paez, A | 1 |
| Moreno, A | 1 |
| Berenguer, A | 1 |
| Zusman, R | 1 |
| Barzilay, JI | 2 |
| Bettencourt, J | 2 |
| Goff, DC | 3 |
| Black, H | 3 |
| Habib, G | 1 |
| Ellsworth, A | 2 |
| Force, RW | 1 |
| Wiegmann, T | 1 |
| Ciocon, JO | 2 |
| Basile, JN | 3 |
| Ebina, T | 1 |
| Kuwajima, I | 1 |
| Morinari, M | 1 |
| Hoshide, Y | 1 |
| Kanazawa, M | 1 |
| Kohzuki, M | 1 |
| Kurosawa, H | 1 |
| Minami, N | 1 |
| Ito, O | 1 |
| Saito, T | 1 |
| Yasujima, M | 1 |
| Abe, K | 1 |
| Hermida, RC | 1 |
| Calvo, C | 3 |
| Ayala, DE | 1 |
| Domínguez, MJ | 1 |
| Covelo, M | 1 |
| Fernández, JR | 1 |
| Fontao, MJ | 1 |
| López, JE | 1 |
| Mediavilla García, JD | 1 |
| Sabio, JM | 1 |
| Fernández-Torres, C | 1 |
| Aliaga Martínez, L | 1 |
| Jiménez-Alonso, J | 1 |
| Mazo, EB | 1 |
| Shashin, MN | 1 |
| Pulcrano, M | 1 |
| Palmieri, EA | 1 |
| Pagano, L | 1 |
| Tauchmanova, L | 1 |
| Rossi, A | 1 |
| Fazio, S | 1 |
| Lombardi, G | 1 |
| Biondi, B | 1 |
| Dell'Omo, G | 2 |
| Penno, G | 2 |
| Pucci, L | 1 |
| Pellegrini, G | 1 |
| Scotti, A | 2 |
| Del Prato, S | 2 |
| Pedrinelli, R | 2 |
| Steers, WD | 1 |
| Hong, SJ | 2 |
| Lee, MS | 1 |
| Gil-Extremera, B | 1 |
| Gomez-Fernández, P | 1 |
| Masramon, X | 1 |
| Pueyo, C | 1 |
| Armada, B | 1 |
| Derosa, G | 2 |
| Cicero, AF | 2 |
| Gaddi, A | 1 |
| Mugellini, A | 1 |
| Ciccarelli, L | 2 |
| Fogari, R | 3 |
| Sakima, A | 1 |
| Takishita, S | 1 |
| Asai, T | 1 |
| Kushiro, T | 3 |
| Fujita, H | 1 |
| Kanmatsuse, K | 2 |
| Hobbs, FR | 1 |
| Khan, T | 1 |
| Collins, B | 1 |
| Wyllie, MG | 1 |
| Hasegawa, K | 2 |
| Kuji, T | 1 |
| Ogawa, N | 1 |
| Shimura, G | 1 |
| Umemura, S | 2 |
| Tochikubo, O | 2 |
| Perlini, S | 2 |
| Palladini, G | 2 |
| Ferrero, I | 2 |
| Tozzi, R | 2 |
| Fallarini, S | 1 |
| Facoetti, A | 1 |
| Nano, R | 1 |
| Clari, F | 2 |
| Busca, G | 2 |
| Ferrari, AU | 2 |
| Hernandez, C | 1 |
| Duran, R | 1 |
| Jara, J | 1 |
| Castaño, I | 1 |
| Moralejo, M | 1 |
| Robles, NR | 1 |
| Gómez Campderá, F | 1 |
| Ocón, I | 1 |
| Manjón, M | 1 |
| Pastors, L | 1 |
| Herrera, J | 1 |
| Villatoro, J | 1 |
| Calls, I | 1 |
| Torrijos, I | 1 |
| Rodríguez Villareal, I | 1 |
| Rodríguez Martínez, MA | 1 |
| Méndez, ML | 1 |
| Morey, A | 1 |
| Martínez Fernández, I | 1 |
| Marco, I | 1 |
| Liébana, A | 1 |
| Rincón, B | 1 |
| Tornero, F | 1 |
| Cheng, TO | 1 |
| Ruiz-Aja, S | 1 |
| Kaplan, SA | 4 |
| DE Rose, AF | 1 |
| O'leary, MP | 1 |
| McVary, KT | 1 |
| Pessina, AC | 5 |
| Ciccariello, L | 1 |
| Perrone, F | 1 |
| Stoico, V | 1 |
| Gussoni, G | 1 |
| Muggeo, M | 1 |
| de Alvaro, F | 1 |
| Hernández-Presa, MA | 1 |
| Keck, M | 1 |
| Meredith, P | 1 |
| Bullen, K | 1 |
| Quinn, S | 1 |
| Koren, A | 1 |
| Mann, SJ | 2 |
| Calò, LA | 1 |
| Bertipaglia, L | 1 |
| Pagnin, E | 1 |
| Davis, PA | 2 |
| Sartori, M | 1 |
| Semplicini, A | 3 |
| Os, I | 3 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Papademetriou, V | 1 |
| Proschan, M | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| D'Angelo, A | 4 |
| Tinelli, C | 1 |
| Piccinni, MN | 1 |
| Pricolo, F | 1 |
| Salvadeo, S | 1 |
| Montagna, L | 1 |
| Gravina, A | 1 |
| Ferrari, I | 1 |
| Galli, S | 1 |
| Paniga, S | 1 |
| Yusuf, S | 1 |
| El-Ghatit, AM | 1 |
| Miller, MB | 1 |
| Yasunari, K | 1 |
| Matsui, T | 1 |
| Maeda, K | 1 |
| Nakamura, M | 1 |
| Watanabe, T | 1 |
| Kiriike, N | 1 |
| Gatti, C | 1 |
| Vezzoli, M | 1 |
| Cesana, F | 1 |
| Janetti, MB | 1 |
| Mancia, G | 2 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Yorulmaz, E | 1 |
| Muqit, MM | 1 |
| Menage, MJ | 1 |
| Nwachuku, CE | 1 |
| Okuno, E | 1 |
| Kakinohana, M | 1 |
| Miyata, Y | 1 |
| Sugahara, K | 1 |
| Tisaire-Sánchez, J | 1 |
| Roma, J | 1 |
| Camacho-Azcargorta, I | 1 |
| Bueno-Gómez, J | 1 |
| Mora-Maciá, J | 1 |
| Navarro, A | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Celik, T | 1 |
| Yenicesu, M | 1 |
| Eyileten, T | 1 |
| Acikel, C | 1 |
| Oguz, Y | 1 |
| Yavuz, I | 1 |
| Vural, A | 1 |
| Hall, GC | 1 |
| McMahon, AD | 1 |
| Cheung, CM | 1 |
| Awan, MA | 1 |
| Peh, KK | 1 |
| Sandramouli, S | 1 |
| Ohta, Y | 1 |
| Tsuchihashi, T | 1 |
| Onaka, U | 1 |
| Eto, K | 1 |
| Ueno, M | 1 |
| Wykretowicz, A | 3 |
| Guzik, P | 3 |
| Krauze, T | 2 |
| Adamska, K | 2 |
| Milewska, A | 2 |
| Wysocki, H | 3 |
| Henriquez, MA | 1 |
| Colon, PJ | 1 |
| Christian, R | 1 |
| Wong, ND | 1 |
| Azuma, Y | 1 |
| Imai, K | 1 |
| Oda, K | 1 |
| Niwa, F | 1 |
| Makino, M | 1 |
| Oshima, F | 1 |
| Harris-Haywood, S | 1 |
| Pressel, S | 1 |
| Baimbridge, C | 1 |
| Bareis, CJ | 1 |
| Dart, R | 1 |
| Gupta, AK | 1 |
| Hamilton, BP | 1 |
| Jafri, SZ | 1 |
| Louis, GT | 1 |
| Whelton, PK | 1 |
| Scott, CL | 1 |
| Simmons, DL | 1 |
| Stanford, C | 1 |
| Takahashi, H | 1 |
| Ikeda, T | 1 |
| Gomi, T | 1 |
| Shibuya, Y | 1 |
| Shinozaki, S | 1 |
| Suzuki, Y | 1 |
| Matsuda, N | 1 |
| Kasacka, I | 1 |
| Majewski, M | 1 |
| Piskorski, J | 1 |
| Wesseling, KH | 1 |
| Ligthart, JJ | 1 |
| Smout, AJ | 1 |
| Birkenhäger, WH | 4 |
| Dominiak, P | 2 |
| Jones, DW | 2 |
| Sands, CD | 1 |
| Fulton, B | 1 |
| Wagstaff, AJ | 1 |
| Sorkin, EM | 1 |
| Gillenwater, JY | 1 |
| Conn, RL | 1 |
| Chrysant, SG | 2 |
| Roy, J | 1 |
| Gaffney, M | 2 |
| Ice, K | 2 |
| Dias, N | 2 |
| Janknegt, RA | 2 |
| Meade-D'Alisera, P | 1 |
| Quiñones, S | 1 |
| Soldo, KA | 1 |
| Ebata, H | 1 |
| Hojo, Y | 1 |
| Ikeda, U | 1 |
| Ishida, H | 1 |
| Natsume, T | 1 |
| Dickerson, JE | 2 |
| Moiseev, VS | 1 |
| Ivleva, AIa | 1 |
| Kobalava, ZhD | 1 |
| Dominguez, LJ | 1 |
| Weinberger, MH | 2 |
| Cefalu, WT | 1 |
| Jacobs, DB | 1 |
| Barbagallo, M | 1 |
| Walsh, MF | 1 |
| Sowers, JR | 1 |
| Young, RL | 1 |
| Jonsson, JR | 1 |
| Mano, MT | 1 |
| Frewin, DB | 1 |
| Head, RJ | 1 |
| González Maqueda, I | 1 |
| Giorda, C | 2 |
| Appendino, M | 2 |
| Mason, MG | 1 |
| Imperiale, E | 1 |
| Pagano, G | 1 |
| Giordano, M | 3 |
| Matsuda, M | 1 |
| Sanders, L | 1 |
| Canessa, ML | 3 |
| DeFronzo, RA | 3 |
| López, E | 1 |
| Barrio, E | 1 |
| Espejo, J | 1 |
| Ruiz, M | 1 |
| Vega, A | 1 |
| Levenstein, M | 3 |
| Walmsley, P | 3 |
| Krakoff, LR | 1 |
| Takata, Y | 1 |
| Yoshizumi, T | 1 |
| Ito, Y | 1 |
| Hirota, Y | 1 |
| Fujishima, M | 2 |
| Fahrenbach, MC | 1 |
| Yurgalevitch, SM | 1 |
| Zmuda, JM | 1 |
| Thompson, PD | 1 |
| Stokes, GS | 3 |
| Johnston, HJ | 1 |
| Okoro, EO | 2 |
| Boutagy, J | 1 |
| Monaghan, JC | 2 |
| Marwood, JF | 3 |
| Ahaneku, JE | 7 |
| Taylor, GO | 4 |
| Agbedana, EO | 4 |
| Walker, O | 4 |
| Salako, LA | 4 |
| Tomten, SE | 2 |
| Kjeldsen, SE | 2 |
| Nilsson, S | 2 |
| Westheim, AS | 2 |
| Cosenzi, A | 1 |
| Waltman, FL | 1 |
| van Es, PN | 3 |
| Yamasaki, Y | 1 |
| Shiba, Y | 1 |
| Sekiya, M | 1 |
| Tsujino, T | 1 |
| Hakui, N | 1 |
| Kawamori, R | 1 |
| Kamada, T | 1 |
| Andersson, PE | 2 |
| Johansson, J | 1 |
| Berne, C | 1 |
| Lithell, H | 2 |
| Rabkin, SW | 1 |
| Huff, MW | 1 |
| Newman, C | 2 |
| Sim, D | 2 |
| Carruthers, SG | 1 |
| Pool, JL | 6 |
| Maheux, P | 1 |
| Facchini, F | 1 |
| Jeppesen, J | 1 |
| Greenfield, MS | 1 |
| Clinkingbeard, C | 1 |
| Chen, YD | 2 |
| Reaven, GM | 2 |
| Tomiyama, H | 1 |
| Abeta, H | 1 |
| Ishii, T | 1 |
| Takahashi, A | 2 |
| Furukawa, L | 1 |
| Asagami, T | 1 |
| Hino, T | 1 |
| Saito, F | 1 |
| Otsuka, Y | 1 |
| Sznajderman, M | 1 |
| Chotkowska, E | 1 |
| Peczkowska, M | 1 |
| Sawicki, M | 1 |
| Janaszek-Sitkowska, H | 1 |
| Wiernikowska-Wegorek, I | 1 |
| Galewicz, A | 1 |
| Cybulska, I | 1 |
| Fernández Pinilla, C | 1 |
| Luque Otero, M | 1 |
| Martell Claros, N | 1 |
| Alcázar de la Osa, JM | 1 |
| Rodicio Díaz, JL | 1 |
| Ruilope Urioste, LM | 1 |
| Neaton, JD | 1 |
| Prineas, RJ | 2 |
| Stamler, J | 1 |
| Grandits, GA | 2 |
| Elmer, PJ | 3 |
| Schoenberger, JA | 2 |
| McDonald, R | 2 |
| Hitzenberger, G | 1 |
| Ganzinger, U | 2 |
| Caldwell, LR | 1 |
| Omvik, P | 4 |
| Ferrara, LA | 1 |
| Di Marino, L | 1 |
| Russo, O | 1 |
| Marotta, T | 1 |
| Mancini, M | 1 |
| Carruthers, G | 1 |
| Dessain, P | 1 |
| Fodor, G | 1 |
| Palmer, W | 1 |
| Stokke, HP | 4 |
| Fauchald, P | 2 |
| Holme, I | 6 |
| Rugstad, HE | 2 |
| Christophersen, BO | 1 |
| Stokke, O | 1 |
| Agbedana, OE | 1 |
| Taylor, OG | 1 |
| Lewis, CE | 2 |
| Grandits, A | 1 |
| Flack, J | 1 |
| Cai, H | 1 |
| Ibayashi, S | 1 |
| Yao, H | 1 |
| Sugimori, H | 1 |
| Sadoshima, S | 1 |
| Puddu, P | 1 |
| Gallucci, M | 1 |
| Curnis, A | 1 |
| Pupita, F | 1 |
| Ansuini, R | 1 |
| Malacco, E | 1 |
| Hernández Hernández, R | 3 |
| Angeli-Greaves, M | 1 |
| Carvajal, AR | 3 |
| Guerrero Pajuelo, J | 2 |
| Armas Padilla, MC | 3 |
| Armas-Hernández, MJ | 1 |
| Gonzalez, NM | 1 |
| Liebson, PR | 2 |
| Mikami, H | 1 |
| Ishimitsu, T | 1 |
| Yagi, S | 2 |
| Sugishita, Y | 1 |
| Fujimura, A | 1 |
| Ebihara, A | 1 |
| Sakamaki, T | 1 |
| Murata, K | 1 |
| Saito, A | 1 |
| Jeng, JR | 1 |
| Sheu, WH | 2 |
| Jeng, CY | 1 |
| Huang, SH | 1 |
| Shieh, SM | 2 |
| Lee, D | 1 |
| Lu, ZW | 1 |
| DeQuattro, V | 1 |
| Sanders, LR | 1 |
| Castellino, P | 2 |
| Jacobs, MC | 1 |
| Lenders, JW | 1 |
| Willemsen, JJ | 1 |
| Thien, T | 1 |
| Bignotti, M | 1 |
| Lamponi, M | 1 |
| Sendo, D | 1 |
| Katsuura, M | 1 |
| Akiba, K | 1 |
| Yokoyama, S | 1 |
| Tanabe, S | 1 |
| Wakabayashi, T | 1 |
| Sato, S | 1 |
| Otaki, S | 1 |
| Obata, K | 1 |
| Yamagiwa, I | 1 |
| Hayasaka, K | 1 |
| Sowunmi, A | 2 |
| Lepor, H | 1 |
| Klimberg, I | 1 |
| Mobley, DF | 1 |
| Fawzy, A | 3 |
| McDonald, RH | 1 |
| Yunis, C | 1 |
| Svendsen, K | 1 |
| Nakamoto, T | 1 |
| Harasawa, H | 1 |
| Momoki, S | 1 |
| Suzuki, H | 1 |
| Horie, Y | 1 |
| Ohnuma, N | 1 |
| Ohno, K | 1 |
| Kato, S | 1 |
| Okuda, M | 1 |
| Iizuka, M | 1 |
| Gorchein, A | 1 |
| Sanz Guajardo, D | 1 |
| Espejo Martínez, J | 1 |
| Evans, M | 1 |
| Perera, PW | 1 |
| Donoghue, J | 1 |
| Abrams, P | 1 |
| Kawano, Y | 1 |
| Watanabe, Y | 1 |
| Miyajima, E | 2 |
| Ishii, M | 2 |
| Solini, A | 1 |
| Raij, L | 1 |
| Hayakawa, H | 1 |
| Coffee, K | 1 |
| Guerra, J | 1 |
| Zehetgruber, M | 1 |
| Christ, G | 1 |
| Gabriel, H | 1 |
| Mundigler, G | 1 |
| Beckmann, R | 1 |
| Binder, BR | 1 |
| Huber, K | 1 |
| Lazebnik, LB | 1 |
| Melichenko, SB | 1 |
| Serebrov, AN | 1 |
| Daae, LN | 4 |
| Westlie, L | 5 |
| Andersen, P | 2 |
| Seljeflot, I | 2 |
| Herzog, A | 1 |
| Arnesen, H | 2 |
| Hjermann, I | 2 |
| D'Alisera, PM | 1 |
| Grzeszczak, W | 2 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Slavachevsky, I | 1 |
| Half-Onn, E | 1 |
| Ravid, M | 1 |
| Calò, L | 1 |
| Cantaro, S | 1 |
| Bonfante, L | 1 |
| Castrignano, R | 2 |
| Carraro, G | 1 |
| Kvam, FI | 1 |
| Ofstad, J | 2 |
| Iversen, BM | 2 |
| Gerdts, E | 2 |
| Svarstad, E | 2 |
| Aanderud, S | 1 |
| Myking, OL | 1 |
| Papadakis, JA | 1 |
| Mikhailidis, DP | 4 |
| Boston, D | 1 |
| Collins, C | 1 |
| Brude, IR | 1 |
| Drevon, CA | 1 |
| Viken, K | 1 |
| Arnstad, JE | 1 |
| Valnes, KN | 1 |
| Nenseter, MS | 1 |
| Pearson, ER | 1 |
| D'Souza, RJ | 1 |
| Hamilton-Wood, C | 1 |
| Nicholls, AJ | 1 |
| Beaman, M | 1 |
| Hendry, A | 1 |
| Cook, E | 1 |
| Gonzalez, F | 2 |
| Aspelin, T | 1 |
| Kierulf, P | 3 |
| Guthrie, RM | 1 |
| Siegel, RL | 1 |
| Maeso, R | 1 |
| Navarro-Cid, J | 1 |
| Rodrigo, E | 1 |
| Lahera, V | 1 |
| Cachofeiro, V | 1 |
| Gessi, S | 1 |
| Caiazza, A | 1 |
| Toth, K | 2 |
| Kesmarky, G | 2 |
| Vekasi, J | 1 |
| Nemes, J | 2 |
| Czopf, L | 2 |
| Kapronczay, P | 2 |
| Halmosi, R | 1 |
| Papp, E | 1 |
| Juricskay, I | 2 |
| Rodríguez-Feo, JA | 3 |
| Fortes, J | 3 |
| Aceituno, E | 1 |
| Farré, J | 2 |
| Ayala, R | 1 |
| Castilla, C | 1 |
| Rico, L | 3 |
| González-Fernández, F | 1 |
| García-Durán, M | 1 |
| Casado, S | 3 |
| López-Farré, A | 3 |
| SoRelle, R | 1 |
| Einecke, D | 1 |
| Miller, JL | 1 |
| Lasagna, L | 1 |
| Sollins, JS | 1 |
| Garofalo, JL | 1 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Reddi, AS | 2 |
| Nimmagadda, VR | 2 |
| Lefkowitz, A | 1 |
| Kuo, HR | 1 |
| Bollineni, JS | 1 |
| Nalbantgil, S | 1 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Chen, BH | 1 |
| Schillaci, G | 1 |
| Verdecchia, P | 1 |
| Geraci, TS | 1 |
| Kingry, C | 1 |
| Kimmel, B | 1 |
| Lusk, C | 1 |
| Parks, H | 1 |
| Nwachuku, C | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Abe, A | 1 |
| Kawamura, Y | 1 |
| Hosoya, T | 1 |
| Jones, CL | 1 |
| Sweeney, ME | 1 |
| Jagroop, IA | 1 |
| Casciano, J | 1 |
| Doyle, J | 1 |
| Casciano, R | 1 |
| Kopp, Z | 1 |
| Marchant, N | 1 |
| Bustacchini, S | 1 |
| Arikian, S | 1 |
| Kim, R | 1 |
| Khan, MA | 2 |
| Milionis, HJ | 1 |
| Morgan, RJ | 2 |
| Arora, R | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Kreder, KJ | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Gerber, LM | 1 |
| Gómez, J | 2 |
| Núñez, A | 1 |
| de Andrés, R | 2 |
| Cabestrero, F | 1 |
| Faulhaber, HD | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Brown, CA | 1 |
| Miller, ME | 1 |
| Hall, JE | 1 |
| Mori, Y | 1 |
| Matsubara, H | 1 |
| Nose, A | 1 |
| Shibasaki, Y | 1 |
| Masaki, H | 1 |
| Kosaki, A | 1 |
| Okigaki, M | 1 |
| Fujiyama, S | 1 |
| Tanaka-Uchiyama, Y | 1 |
| Hasegawa, T | 1 |
| Iba, O | 1 |
| Tateishi, E | 1 |
| Amano, K | 1 |
| Iwasaka, T | 1 |
| Simon, HB | 1 |
| Ebbs, D | 1 |
| Hirano, T | 1 |
| Yoshino, G | 1 |
| Kashiwazaki, K | 1 |
| Adachi, M | 1 |
| Messerli, FH | 1 |
| Poulter, N | 1 |
| García-Colis, E | 1 |
| López-Blaya, A | 1 |
| Deary, AJ | 1 |
| Schumann, AL | 1 |
| Murfet, H | 1 |
| Haydock, SF | 1 |
| Foo, RS | 1 |
| Komai, N | 1 |
| Ohishi, M | 1 |
| Moriguchi, A | 1 |
| Yanagitani, Y | 1 |
| Jinno, T | 1 |
| Matsumoto, K | 1 |
| Katsuya, T | 1 |
| Rakugi, H | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Martínez-Castelao, A | 1 |
| Hueso, M | 1 |
| Rejas, J | 1 |
| Sarrias, J | 1 |
| Alsina, J | 1 |
| Sanz de Burgoa, V | 1 |
| Martínez, J | 1 |
| Gil de Miguel, A | 1 |
| Ocharán-Corcuera, J | 1 |
| Iribar, I | 1 |
| Saracho, R | 1 |
| Martínez, I | 1 |
| Montenegro, J | 1 |
| Macphee, GJ | 1 |
| Curzio, J | 1 |
| Farish, E | 1 |
| Reid, JL | 6 |
| Elliott, HL | 5 |
| Krusell, LR | 2 |
| Christensen, CK | 1 |
| Pedersen, OL | 1 |
| Tierney, G | 1 |
| Johnston, H | 1 |
| Babamoto, KS | 1 |
| Hirokawa, WT | 1 |
| Agabiti-Rosei, E | 1 |
| Muiesan, ML | 1 |
| Rizzoni, D | 1 |
| Zulli, R | 1 |
| Calebich, S | 1 |
| Beschi, M | 1 |
| Castellano, M | 1 |
| Muiesan, G | 1 |
| Leren, P | 2 |
| Kooman, JP | 1 |
| Wijnen, JA | 1 |
| Draaijer, P | 1 |
| van Bortel, LM | 1 |
| Gladziwa, U | 1 |
| Peltenburg, HG | 1 |
| Struyker-Boudier, HA | 1 |
| van Hooff, JP | 1 |
| Leunissen, KM | 1 |
| Donnelly, R | 4 |
| Meredith, PA | 3 |
| Howie, CA | 2 |
| Bodansky, HJ | 1 |
| McLaughlin, B | 1 |
| Daly, L | 1 |
| Devlin, JG | 1 |
| Huupponen, R | 1 |
| Lehtonen, A | 3 |
| Vähätalo, M | 1 |
| Shen, DC | 1 |
| Fuh, MM | 1 |
| de Planque, BA | 1 |
| Englert, RG | 2 |
| Barlage, U | 1 |
| Khoury, AF | 1 |
| Kaplan, NM | 1 |
| Passarelli, P | 1 |
| Galiè, N | 1 |
| Limonetti, P | 1 |
| Branzi, A | 1 |
| Magnani, B | 1 |
| Sumner, DJ | 1 |
| Langdon, CG | 1 |
| Naber, FB | 1 |
| Talseth, T | 4 |
| Daae, L | 4 |
| Taylor, SH | 5 |
| Wessels, F | 1 |
| Fukiyama, K | 1 |
| Omae, T | 1 |
| Iimura, O | 1 |
| Yoshinaga, K | 2 |
| Inagaki, Y | 1 |
| Kaneko, Y | 2 |
| Yamada, K | 1 |
| Ijichi, H | 1 |
| Maslowski, AH | 1 |
| Silva, H | 2 |
| Fonseca, R | 2 |
| Marshall, D | 1 |
| Bonnet, G | 1 |
| Harmse, DP | 1 |
| Manos, J | 1 |
| Corral, JL | 1 |
| López, NC | 1 |
| Pecorelli, A | 1 |
| Rincón, LA | 1 |
| Terán, VD | 1 |
| Monsalve, P | 1 |
| Vera, O | 1 |
| Pérez Acuña, F | 1 |
| Medina, O | 1 |
| Ostojich, K | 1 |
| López, B | 1 |
| Torres, N | 1 |
| Lugo de Franco, V | 1 |
| Catalano, M | 1 |
| Libretti, A | 1 |
| Armas de Hernandez, MJ | 2 |
| Barragan, O | 2 |
| Boada Boada, JJ | 2 |
| Roa, E | 1 |
| Guerrero Pajuelo, JR | 1 |
| Oliveros-Palacios, MC | 1 |
| Godoy-Godoy, N | 1 |
| Colina-Chourio, JA | 1 |
| Nosadini, R | 1 |
| Crepaldi, G | 2 |
| Feher, MD | 2 |
| Brusletto, B | 2 |
| Westheim, A | 3 |
| Syvertsen, JO | 2 |
| Jansson, JH | 1 |
| Johansson, B | 1 |
| Boman, K | 1 |
| Nilsson, TK | 1 |
| Myhre, K | 1 |
| Brinchmann-Hansen, O | 1 |
| Lindgren, B | 1 |
| Lenz, ML | 1 |
| Taylor, AA | 2 |
| Maclean, D | 1 |
| McDevitt, DG | 1 |
| Henderson, AD | 1 |
| Wadsworth, J | 1 |
| Poulter, C | 1 |
| Gelding, S | 1 |
| Richmond, W | 1 |
| Elkeles, RS | 1 |
| Lecerof, H | 1 |
| Bornmyr, S | 1 |
| Lilja, B | 1 |
| De Pedis, G | 1 |
| Hulthén, UL | 1 |
| Groppelli, A | 1 |
| Omboni, S | 1 |
| Oliver, RM | 1 |
| Upward, JW | 1 |
| Dewhurst, AG | 1 |
| Honeywell, R | 1 |
| Renwick, AG | 1 |
| Waller, DG | 1 |
| Aursnes, I | 1 |
| Searle, M | 1 |
| Dathan, R | 1 |
| Dean, S | 1 |
| Christensen, CC | 1 |
| Anderton, JL | 1 |
| Notghi, A | 1 |
| Lijnen, P | 3 |
| Fagard, R | 3 |
| Staessen, J | 3 |
| Amery, A | 3 |
| Mozzato, MG | 2 |
| Serena, L | 2 |
| Valle, R | 2 |
| Casolino, P | 2 |
| Buzzaccarini, F | 2 |
| Rubino, N | 2 |
| Giusto, M | 1 |
| Shionoiri, H | 1 |
| Yoshimura, H | 1 |
| Miyakawa, T | 1 |
| Takagi, N | 1 |
| Chichester, CO | 1 |
| Rodgers, RL | 1 |
| Louis, WJ | 2 |
| McNeil, JJ | 2 |
| Anavekar, SN | 1 |
| Conway, EL | 2 |
| Workman, B | 1 |
| Howes, LG | 2 |
| Drummer, OH | 2 |
| Jarrott, B | 1 |
| Dzau, VJ | 1 |
| Lissens, W | 1 |
| Gillin, AG | 1 |
| Fletcher, PJ | 1 |
| Horvath, JS | 1 |
| Hutton, BF | 1 |
| Bautovich, GJ | 1 |
| Tiller, DJ | 1 |
| Meng, L | 1 |
| Raymond, K | 1 |
| Ames, RP | 2 |
| Schnaper, HW | 1 |
| Spann, S | 1 |
| Velasquez, MT | 1 |
| Kiyasu, JY | 1 |
| Nelson, EB | 2 |
| Biernacki, W | 1 |
| Flenley, DC | 1 |
| Casiglia, E | 1 |
| Vincent, J | 1 |
| Hayduk, K | 2 |
| Rosenthal, J | 3 |
| Frick, MH | 2 |
| Cox, DA | 2 |
| Himanen, P | 4 |
| Huttunen, M | 2 |
| Pitkäjärvi, T | 2 |
| Pörsti, P | 2 |
| Pöyhönen, L | 2 |
| Pyykönen, ML | 2 |
| Reinikainen, P | 2 |
| Salmela, P | 2 |
| Torvik, D | 2 |
| Madsbu, HP | 2 |
| Ott, P | 1 |
| Storm, TL | 1 |
| Jensen, H | 1 |
| Badskjaer, J | 1 |
| Faergeman, O | 1 |
| Wilner, KD | 1 |
| Ziegler, MG | 1 |
| Nash, DT | 1 |
| Schonfeld, G | 1 |
| Reeves, RL | 1 |
| Weidler, DJ | 2 |
| Schneider, HT | 1 |
| Trost, BN | 1 |
| Weidmann, P | 1 |
| Riesen, W | 1 |
| Claessens, J | 1 |
| Streulens, Y | 1 |
| Nelemans, F | 1 |
| de Bos, R | 2 |
| Young, RA | 1 |
| Brogden, RN | 1 |
| van den Hogen, AL | 1 |
| Bartels, AC | 1 |
| de Vries, PM | 1 |
| Oe, LP | 1 |
| van Bronswÿk, H | 1 |
| Donker, AJ | 1 |
| Réveillaud, RJ | 1 |
| Fillastre, JP | 1 |
| Zech, P | 1 |
| Soltero, I | 1 |
| Guevara, J | 1 |
| Velasco, M | 1 |
| Miura, Y | 1 |
| Pati, T | 1 |
| Al Awady, M | 1 |
| Tronca, R | 1 |
| Vatle, S | 1 |
| Giorgi, G | 1 |
| Legramante, JM | 1 |
| Fioravanti, G | 1 |
| Paies, G | 1 |
| Legramante, A | 1 |
| Nechwatal, W | 2 |
| Berger, J | 1 |
| Blumrich, W | 1 |
| Bouzo, H | 1 |
| Brandl, K | 1 |
| Braun, S | 1 |
| Laukaitis, A | 1 |
| Müller, G | 1 |
| Ryba, W | 1 |
| Schreiegg, J | 1 |
| Lindner, UK | 1 |
| von Manteuffel, GE | 1 |
| Stafunsky, M | 1 |
| Lee, PS | 1 |
| Sharma, SK | 1 |
| Mauersberger, H | 1 |
| Haugland, H | 1 |
| Halttunen, P | 1 |
| Baez, MA | 1 |
| Garg, DC | 1 |
| Jallad, NS | 1 |
| Saraste, M | 2 |
| Niittymäki, K | 1 |
| Marniemi, J | 1 |
| Leader, JP | 1 |
| Milson, JA | 1 |
| Singleton, W | 1 |
| Cubeddu, LX | 2 |
| Fuenmayor, N | 1 |
| Caplan, N | 1 |
| Ferry, D | 1 |
| Faulkner, JK | 1 |
| Karjalainen, U | 1 |
| Hjortdahl, P | 1 |
| von Krogh, H | 1 |
| Scott, PJ | 1 |
| Hosie, J | 1 |
| Scott, MG | 1 |
| Bloomfield, R | 1 |
| Klotman, PE | 1 |
| Pickering, BI | 1 |
| Wombolt, DG | 1 |
| Halperin, A | 1 |
| Smyth, P | 1 |
| Pringle, S | 1 |
| Jackson, G | 1 |
| Lorimer, AR | 1 |
| Conrad, KA | 1 |
| Fagan, TC | 1 |
| Mackie, MJ | 1 |
| Mayshar, PV | 1 |
| Lee, S | 1 |
| Souhrada, JF | 1 |
| Falkner, FC | 1 |
| Lazar, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension[NCT00994617] | Phase 4 | 600 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension[NCT02901977] | Phase 4 | 71 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Optimum Treatment for Drug-Resistant Hypertension[NCT02369081] | Phase 4 | 348 participants (Actual) | Interventional | 2009-05-31 | Active, not recruiting | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial[NCT03476616] | Phase 4 | 330 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings[NCT00285519] | Phase 4 | 600 participants | Interventional | 2003-08-31 | Completed | ||
| Prospective Multicenter Open-label One Arm Trial Investigating a Pumpkin Seed, Isoflavonoid and Cranberry Mix in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia[NCT04146103] | 163 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| [NCT00000522] | Phase 2 | 0 participants | Interventional | 1985-08-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction[NCT00382161] | Phase 3 | 20 participants (Anticipated) | Interventional | 2006-10-31 | Withdrawn (stopped due to not enough patients meeting inclusion criteria) | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| Influence of the Autonomic Nervous System on Endothelial Function as an Acute Response to Exercise in Hypertensive Individuals: a Randomized Double-blind Protocol Study[NCT04371757] | 39 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
49 reviews available for doxazosin and Hypertension
| Article | Year |
|---|---|
Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents | 2022 |
Role of α1-blockers in the current management of hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Aldosterone; Antihypertensive Agents; Diuretics; Doxazosin; Huma | 2022 |
Recent advances in understanding and managing resistant/refractory hypertension.
Topics: Antihypertensive Agents; Bisoprolol; Catheters; Clinical Trials as Topic; Clonidine; Denervation; Do | 2020 |
Three drugs and still hypertensive: what's left?
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Drug Therapy, Combination; Humans; H | 2016 |
Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2010 |
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; In | 2011 |
[Preoperative α-receptor block in patients with pheochromocytoma? Against].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Asymptomatic Diseases; Blood Pressure; Catech | 2012 |
The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both.
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Erectile Dysfunction; Humans; Hypertension; Male; Mid | 2002 |
[Policy of antihypertensive therapy in arterial hypertension in the elderly. II].
Topics: Acrylates; Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor | 2002 |
Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension.
Topics: Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Male; Randomize | 2003 |
Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Delayed-Action Preparations; Doxazosin; Humans; H | 2003 |
Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Humans; Hyp | 2004 |
[Alpha blocker for protection against hypertensive target-organ damage].
Topics: Adrenergic alpha-Antagonists; Binding, Competitive; Blood Pressure; Cardiovascular Diseases; Circadi | 2004 |
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
Clinical ease of using doxazosin in BPH patients with and without hypertension.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Humans; Hypertension; Male; Prostatic | 2005 |
[Therapeutic strategy for morning blood pressure elevation in elderly hypertensives].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2005 |
One drug fits all.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Combinations; Drug Industry; Drug Therapy, Combination | 2005 |
Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Doxazosin | 2006 |
Doxazosin in metabolically complicated hypertension.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Diet, Sodium-Restricted; Dose-Response Relat | 2007 |
Doxazosin in the current treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Dosage Forms; Doxazosin; Drug | 2008 |
[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine].
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Trials as Topic; Doxazosin; Hemodynamics; | 1995 |
Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Dosage Forms; Doxazosin; Drug Evaluation; Heart Ve | 1995 |
Profile of doxazosin in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Pros | 1995 |
Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
Topics: Aged; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Middle Aged; Prostatic Hyperplasia; Uro | 1995 |
Perspectives on the management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Pros | 1995 |
[Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Receptors, Adrenergic, alpha; Sympath | 1993 |
[Alpha-blocker].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Antihypertensive Agents; Diagnosis, Different | 1995 |
[Use of doxazosin (Cardura-Pfizer), alpha 1-adrenoreceptor antagonist, in treatment of hypertension in patients with diabetes].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Animals; Diabetic Angiopathies; Doxazosin; Humans; Hyperc | 1998 |
Doxazosin in elderly patients with hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Doxazosin; Drug Interactions; Humans; Hypertension | 2000 |
[Cardura XL--a unique drug formulation--doxazosine administered in a slow-release form (doxazosine GITS)].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Area Under Curve; Delayed-Action Preparations; Doxazosin; | 2000 |
The treatment of hypertension in patients with erectile dysfunction.
Topics: Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hypertensi | 2000 |
Doxazosin and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme | 2001 |
Doxazosin: a new alpha 1-adrenergic antagonist.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Hemodynamics | 1992 |
The cardiovascular effects of alpha-receptor blocking agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Cardiomegaly; Cardiovascular System; | 1992 |
Alpha-blocker therapy of hypertension. An unfulfilled promise.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
Topics: Antihypertensive Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Doxazosin; Humans; | 1991 |
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
Doxazosin therapy in the treatment of diabetic hypertension.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hypertension; Lipids; Lipopro | 1991 |
New drugs for hypertension--variations on old themes.
Topics: Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Doxazosin; Human | 1991 |
Efficacy and tolerance of doxazosin: a review.
Topics: Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Forecasting; Humans; Hypertension; Lipo | 1990 |
Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Pressure; Clonidine; Doxazosin; Human | 1987 |
Factors influencing the lipid response to selective alpha 1-inhibition.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Diet; Doxazosin; Humans; H | 1989 |
[New specialty drugs registered in Austria. Supressin].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Humans; Hypertens | 1989 |
Clinical pharmacotherapeutics of doxazosin.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Hemodynamics; Humans; Hypertension; Prazo | 1989 |
Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Hemodynamics; Humans; Hypertension; Muscle, Smooth | 1989 |
Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Doxazosin; Humans; Hydrochlorothiazide; H | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertensi | 1989 |
Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Dogs; Doxa | 1988 |
Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Dose-Response Relationship, | 1988 |
222 trials available for doxazosin and Hypertension
| Article | Year |
|---|---|
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cardiovascular Dise | 2017 |
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relation | 2017 |
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 2018 |
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2013 |
Effects of doxazosin as the third agent on morning hypertension and position-related blood pressure changes in diabetic patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
[PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Diuretics; Doxazosin; Drug Therapy, Combination | 2015 |
PURLs: Resistant hypertension? Time to consider this fourth-line drug.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bi | 2016 |
The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2017 |
Effect of doxazosin on the left ventricular structure and function in morning hypertensive patients: the Japan Morning Surge 1 study.
Topics: Aged; Antihypertensive Agents; Circadian Rhythm; Doxazosin; Echocardiography; Female; Humans; Hypert | 2008 |
Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Glucose; Blood Pressure; Dose-Response | 2008 |
[Clinical and neuroimmunoendocrine effects of doxasosine in treatment of arterial hypertension accompanied by prostate benign hyperplasia in elderly people].
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Doxazosin; Follow-Up Studies; | 2008 |
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2007 |
Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Biomar | 2008 |
Orthostatic hypertension detected by self-measured home blood pressure monitoring: a new cardiovascular risk factor for elderly hypertensives.
Topics: Aged; Aged, 80 and over; Aging; Albuminuria; Antihypertensive Agents; Autonomic Nervous System Disea | 2008 |
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Circ | 2009 |
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Confidence Intervals; Double-Blind Meth | 2009 |
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Comorbidity; Doxazosin; Humans; Hydrox | 2009 |
A double-blind, crossover study of Doxazosin and Enalapril on peripheral vascular tone and nocturnal blood pressure in sleep apnea patients.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Am | 2010 |
Blood pressure-lowering effect and duration of action of bedtime administration of doxazosin determined by home blood pressure measurement.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2010 |
[Series, clinical study from Japan and its reflections; Japan Morning Surge-1 (JMS-1) study].
Topics: Adrenergic alpha-1 Receptor Antagonists; Albuminuria; Doxazosin; Humans; Hypertension; Natriuretic P | 2011 |
Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2012 |
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll | 2012 |
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t
Topics: Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Chlorthalidone; Double-Blind Method; D | 2002 |
[Management of hypertensive patients with left ventricular hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2002 |
Effect of doxazosin on arterial elasticity: functional versus structural changes.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Arteries; | 2002 |
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
Topics: Aldosterone; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Confounding Factors, | 2002 |
Effects of doxazosin and propranolol on A2A adenosine receptors in essential hypertension.
Topics: Adenosine-5'-(N-ethylcarboxamide); Adult; Antihypertensive Agents; Binding, Competitive; Blood Press | 2002 |
Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Disease Progression; Diuretics; D | 2002 |
The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Chlorthalidone; Diuretics; | 2003 |
Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients.
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Body Mass Index; Delayed-Action | 2003 |
Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 2003 |
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Coronary Dise | 2003 |
Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Dose-Resp | 2003 |
Doxazosin GITS trough to peak ratio and 24-hour blood pressure monitoring in the management of hypertension in renal transplant patients.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Doxazosin; Female; H | 2003 |
Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Adult; Aged; Blood Flow Velocity; Blood Glucose; Cross- | 2003 |
Effect of doxazosin on insulin resistance in hypertensive patients with obesity.
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Doxazosin; Female; Humans | 2003 |
Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cholesterol; Do | 2003 |
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Cohort Studi | 2004 |
Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system.
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Br | 2004 |
Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ch | 2004 |
Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Dose-Response Relationship, Drug; Doxazosin; Drug A | 2005 |
Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Delayed-Act | 2005 |
Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.
Topics: Adult; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-B | 2005 |
Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; A | 2005 |
Effect of doxazosin gastrointestinal therapeutic system on platelet degranulation and platelet-leukocyte microaggregate formation induced by physiologic shear stress in hypertension.
Topics: Blood Platelets; Calcium; Carotid Artery Diseases; Cell Degranulation; Doxazosin; Female; Flow Cytom | 2006 |
Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Topics: Aged; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Prostate-Specific Antigen; Prostatic Hy | 2005 |
Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Are | 2006 |
Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Delayed-Action Pre | 2006 |
Controlled-release doxazosin as combination therapy in hypertension: the GATES study.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Delayed-Action Preparations; Doxazosin; | 2006 |
Controlled-release doxazosin as combination therapy in hypertension: the GATES study.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Delayed-Action Preparations; Doxazosin; | 2006 |
Controlled-release doxazosin as combination therapy in hypertension: the GATES study.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Delayed-Action Preparations; Doxazosin; | 2006 |
Controlled-release doxazosin as combination therapy in hypertension: the GATES study.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Delayed-Action Preparations; Doxazosin; | 2006 |
Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Follow-Up Studies; Gene Expressio | 2006 |
Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Blood Pressure; Dose-Response | 2006 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; C-Reactive Protein; Doxazosin; Female; H | 2006 |
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Chlorthalido | 2007 |
Anxiety-induced plasma norepinephrine augmentation increases reactive oxygen species formation by monocytes in essential hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antihypertensive Agents; Anxiety; Atherosclerosis; Bl | 2006 |
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Ag | 2006 |
Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 2006 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2007 |
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Canada; Chlorthal | 2007 |
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Double-B | 2008 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension: the Japan Morning Surge-1 Study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Blood Pressure D | 2008 |
Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system.
Topics: Antihypertensive Agents; Autonomic Nervous System; Baroreflex; Blood Pressure; Cardiovascular System | 2008 |
Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Hea | 1982 |
Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Doxazosi | 1993 |
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Heart Rate; | 1995 |
Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
Topics: Aged; Blood Pressure; Double-Blind Method; Doxazosin; Humans; Hypertension; Male; Prostatic Hyperpla | 1995 |
Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Humans; Hypertension; Male; Middle Ag | 1995 |
Differential effects of an alpha 1-blocker (doxazosin) on diurnal blood pressure variation in dipper and non-dipper type hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 1995 |
Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blo | 1995 |
[Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].
Topics: Adult; Aged; Cholesterol; Dose-Response Relationship, Drug; Doxazosin; Edema; Female; Headache; Huma | 1995 |
Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Cholesterol; | 1994 |
Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, | 1995 |
Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Doxazosin; Drug Admi | 1994 |
Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group.
Topics: Adult; Aged; Aging; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Data Interpretation, Stat | 1994 |
Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Doxazosin; Humans; H | 1995 |
Effect of doxazosin or atenolol on exercise performance in physically active, hypertensive men.
Topics: Adult; Aged; Atenolol; Cross-Over Studies; Double-Blind Method; Doxazosin; Exercise Test; Humans; Hy | 1995 |
Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients.
Topics: Acetylcholinesterase; Adult; Aged; Blood Pressure; Cross-Over Studies; Double-Blind Method; Doxazosi | 1994 |
Combined effect of a low fat diet and doxazosin on blood pressure control and blood lipids. Hunter Hypertension Research Group.
Topics: Adult; Aged; Blood Glucose; Blood Pressure Monitoring, Ambulatory; Diet, Fat-Restricted; Doxazosin; | 1994 |
Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method | 1994 |
Effect of alpha 1-adrenoceptor blockade on maximal VO2 and endurance capacity in well-trained athletic hypertensive men.
Topics: Adrenergic alpha-Antagonists; Adult; Double-Blind Method; Doxazosin; Exercise Test; Hemodynamics; Hu | 1994 |
Doxazosin versus nitrendipine: a double-blind comparative study in patients adhering to a sodium-restricted diet.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Diet, Sodium-Restricted; Double-Blind Method; Doxa | 1994 |
Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity.
Topics: Adult; Aged; Atenolol; Carbohydrate Metabolism; Double-Blind Method; Doxazosin; Female; Hemodynamics | 1994 |
Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
Topics: Apolipoproteins E; Atenolol; Blood Pressure; Double-Blind Method; Doxazosin; Humans; Hypertension; L | 1994 |
Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Doxazosin; Female; Follow-Up Studies; Gluco | 1993 |
[Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme].
Topics: Adult; Aged; Doxazosin; Enalapril; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
[Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; Female; | 1993 |
Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study.
Topics: Adult; Aged; Blood Pressure; Captopril; Doxazosin; Female; Heart Rate; Humans; Hypercholesterolemia; | 1993 |
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Doxazos | 1993 |
[Doxazosin (Carduran)--a research survey].
Topics: Aged; Cholesterol, HDL; Doxazosin; Drug Evaluation; Female; Follow-Up Studies; Humans; Hypertension; | 1993 |
[Effect of 1-alpha blockader on maximal oxygen consumption and physical endurance in hypertensive men].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind M | 1996 |
Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Body Mass Index; Cholesterol; Choles | 1995 |
Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Doxazosin; Enalapril; Female; | 1996 |
Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dis | 1996 |
[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension].
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Body Weight; D | 1995 |
Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow.
Topics: Adult; Aged; Antihypertensive Agents; Body Mass Index; Double-Blind Method; Doxazosin; Enalapril; Fe | 1996 |
Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive | 1996 |
Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind | 1996 |
Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antihypertensive Agents; Bloo | 1996 |
Neural mechanisms in primary hypertension. Efficacy of alpha-blockade with doxazosin during stress.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Doxazosin; Exercise; Female; Humans; Hypertensi | 1996 |
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1996 |
[Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension].
Topics: Albuminuria; Antihypertensive Agents; Doxazosin; Echocardiography; Female; Heart; Humans; Hypertensi | 1996 |
Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cross-Ov | 1996 |
Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Creatinine; Cr | 1996 |
Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Male; Middle Aged | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
[Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Calcium Channel Blockers; Doxazosin; F | 1997 |
Open trial of doxazosin in hypertensive Africans: dose finding, efficacy and safety studies.
Topics: Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Cholesterol; Doxazosin; Drug Mon | 1996 |
Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Denmark; Double-Blind Method; Doxazosin; Humans; Hypertension; Male; N | 1997 |
Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadi | 1997 |
Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Antiporters; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; D | 1997 |
[Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Female; Hemodynamics; Humans; H | 1998 |
A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood | 1998 |
Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
Topics: Adult; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Doxazosin; Female; Fibrinolysis; Gonadal | 1998 |
Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Double-Blind Method; Doxazosin; Electrocardiography | 1998 |
Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; An | 1998 |
Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Coronary Disease; Diabetes Me | 1998 |
Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; D | 1998 |
Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Digestive System; | 1999 |
Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Double-Blind Method; Doxazosin; Follow-Up | 1999 |
Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atenolol; | 1999 |
Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Asthenia; Blood Pressure; Delayed-Action Pr | 1999 |
Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin : results from the HALT study.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Doxa | 2000 |
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Chlorthalidone; Diuretics; Doxazosin; Female | 2000 |
[ALLHAT Study: doxazosin arm is discontinued. Alpha blocker is less effective than a diuretic].
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Coronary Dis | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Met | 2000 |
Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Doxazosin; Drug | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; | 2001 |
[Ambulatory blood pressure monitoring in hypertensive CAPD patients].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulator | 2000 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure Monitorin | 2001 |
A comparison of selected antihypertensives and the use of conventional vs ambulatory blood pressure in the detection and treatment of hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Bendroflumethiazide; Blood P | 2001 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation.
Topics: Adrenergic alpha-Antagonists; Aorta; Arteriosclerosis; Doxazosin; Elasticity; Endothelium, Vascular; | 2002 |
Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Press | 2002 |
Placebo-controlled trial of doxazosin in management of patients with hypertension and hypercholesterolaemia.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cholesterol; Doxazosin; Female; Humans; Hypercholeste | 1992 |
Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Doxazosi | 1992 |
Increase in serum total angiotensin-converting enzyme activity with enalapril therapy in humans: a controlled trial.
Topics: Double-Blind Method; Doxazosin; Drug Administration Schedule; Enalapril; Female; Humans; Hypertensio | 1992 |
Doxazosin: a new alpha 1-adrenergic antagonist.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Hemodynamics | 1992 |
Doxazosin in the management of hypertensive diabetes--a cautionary note (?).
Topics: Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus; Doxazosin; Humans; Hypertension; | 1992 |
A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Coronary Disease; Diuretics; Double-Blind Meth | 1991 |
The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Female; | 1991 |
[Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Enalapril; | 1991 |
Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; D | 1991 |
Vascular pressor responses in treated and untreated essential hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Pressure; Catecholamines; D | 1990 |
Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience.
Topics: Antihypertensive Agents; Blood Pressure; Cholesterol; Coronary Disease; Doxazosin; Female; Heart Rat | 1991 |
Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
Topics: Antihypertensive Agents; Cholesterol; Cohort Studies; Coronary Disease; Doxazosin; England; Family P | 1991 |
An open, noncomparative study of doxazosin in essential hypertension: experience in general practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Fe | 1991 |
Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
Topics: Antihypertensive Agents; Coronary Disease; Double-Blind Method; Doxazosin; Enalapril; Family Practic | 1991 |
A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; | 1991 |
Clinical experience with doxazosin in general medical practice in New Zealand.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Doxazosin in the treatment of essential hypertension in general medical practice in Latin America.
Topics: Antihypertensive Agents; Argentina; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Femal | 1991 |
A multicenter study of doxazosin in the treatment of essential hypertension in France.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; France; | 1991 |
Clinical experience with doxazosin in general medical practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice.
Topics: Antihypertensive Agents; Cholesterol; Doxazosin; Drug Therapy, Combination; Family Practice; Female; | 1991 |
Doxazosin in the treatment of mild or moderate essential hypertension: an echocardiographic study.
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Doxazosin; Echocardiography; Female; Humans; Hypertens | 1991 |
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; F | 1991 |
Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; England; Female; Humans; Hyperten | 1991 |
A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication.
Topics: Antihypertensive Agents; Doxazosin; Female; Humans; Hypertension; Intermittent Claudication; Male; M | 1991 |
Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; | 1991 |
Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Doxazosin; Drug Administration Schedule; Female | 1991 |
Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Doxazosin; Female; Finland; Humans; Hypertension; Ins | 1991 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi | 1991 |
Dose-response clarification in early drug development.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Enalapril; Hum | 1991 |
Doxazosin in 'resistant' hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Diuretics; Doxazosin; Drug Therapy, Combination; Female; H | 1990 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1990 |
Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Double-Blind Method; Doxazosin; Female; Humans; Hyper | 1990 |
Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Atenolol; Blood Pressure; Doxazosin; Heart Rate; Humans; Hypert | 1990 |
Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Atenolol; Double-Blind Method; Doxazosin; Fem | 1990 |
Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Dox | 1990 |
A long-term study of atenolol and doxazosin in mild and moderate hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Fema | 1990 |
Efficacy and tolerance of doxazosin: a review.
Topics: Blood Pressure; Cholesterol; Double-Blind Method; Doxazosin; Forecasting; Humans; Hypertension; Lipo | 1990 |
An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency.
Topics: Acute Kidney Injury; Adult; Blood Pressure; Doxazosin; Female; Heart Rate; Humans; Hypertension; Mal | 1990 |
Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Doxazosin; Drug | 1990 |
Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1988 |
Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Double-Blin | 1989 |
Comparison of doxazosin and atenolol in mild hypertension, and effects on exercise capacity, hemodynamics and left ventricular function.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Do | 1989 |
Effectiveness of doxazosin in systemic hypertension.
Topics: Adult; Antihypertensive Agents; Body Weight; Double-Blind Method; Doxazosin; Drug Administration Sch | 1989 |
[New specialty drugs registered in Austria. Supressin].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Humans; Hypertens | 1989 |
Concentration-effect relationships and individual responses to doxazosin in essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; Female; | 1989 |
Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1989 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertensi | 1989 |
Effects of oral antihypertensive agents on blood lipid levels.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cl | 1986 |
Efficacy and safety of doxazosin in hypertension therapy.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind M | 1987 |
A multicenter trial of doxazosin in West Germany.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Doxazo | 1987 |
Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Met | 1987 |
Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Top | 1987 |
An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double | 1987 |
Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Top | 1987 |
Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Dopamine beta-Hydroxylase; Doxazosin; Female; | 1987 |
A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Double-Bl | 1987 |
Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double | 1987 |
Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials | 1987 |
Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Dogs; Doxa | 1988 |
A multicenter study of doxazosin in the treatment of severe essential hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxa | 1988 |
Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Catecho | 1988 |
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary D | 1988 |
A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Doxazosin; | 1988 |
A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Enala | 1988 |
Alpha-adrenoceptors and the kidney.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Kidney; Prazosin; Receptors, Adrenerg | 1988 |
A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1986 |
Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1986 |
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Do | 1986 |
Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins; Atenolol; Cholesterol; Cholesterol, HDL; Clin | 1986 |
The antihypertensive effects of doxazosin: a clinical overview.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cholesterol | 1986 |
Clinical pharmacology of doxazosin in patients with essential hypertension.
Topics: Adult; Blood Pressure; Blood Proteins; Doxazosin; Female; Half-Life; Heart Rate; Humans; Hypertensio | 1987 |
The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Bli | 1987 |
A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart | 1987 |
[Doxazosin and nitrendipine. A double-blind comparative study in patients with mild to moderate hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Fema | 1987 |
A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazo | 1988 |
Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension.
Topics: Blood Pressure; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Nore | 1988 |
24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Human | 1988 |
Doxazosin in patients with hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Half-Life; Heart Rate; Humans; Hy | 1988 |
205 other studies available for doxazosin and Hypertension
| Article | Year |
|---|---|
2,4-diamino-6,7-dimethoxyquinazolines. 1. 2-[4-(1,4-benzodioxan-2-ylcarbonyl)piperazin-1-yl] derivatives as alpha 1-adrenoceptor antagonists and antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Brain; Dioxanes; Dio | 1987 |
The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof.
Topics: Aldosterone; Antihypertensive Agents; Doxazosin; Humans; Hydralazine; Hyperaldosteronism; Hypertensi | 2023 |
Demographic and clinical profile of black patients with chronic kidney disease attending a tertiary hospital in Johannesburg, South Africa.
Topics: Acidosis; Aged; Allopurinol; Anemia; Bicarbonates; Cross-Sectional Studies; Diabetes Mellitus; Doxaz | 2022 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopath | 2023 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
Unexpected bradycardia after a first dose of doxazosin.
Topics: Antihypertensive Agents; Bradycardia; Doxazosin; Humans; Hypertension | 2022 |
Pheochromocytoma: A three-decade clinical experience in a multicenter study.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Age | 2021 |
The effect of the bedtime-dosing doxazosin on nocturnal hypoxia-triggered blood pressure surge in a young adult man with severe obstructive sleep apnea syndrome and a history of three recurrent sleep-onset strokes.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Doxazosin; Humans; H | 2017 |
All sorts of tests, only one question: an unexpected cause of hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Diagnosis, Differential; Doxazosin; Female; Glycyrrhi | 2017 |
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Female; Hemo | 2018 |
Tako-Tsubo cardiomyopathy induced by pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Atrial Fibrillation; Diagnosis, Differential; Doxazosi | 2018 |
The interrelation of endothelial function and microvascular reactivity in different vascular beds, and risk assessment in hypertension: results from the Doxazosin-ramipril study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2019 |
Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Androgens; Animals; Cells, Cultured; Cyclic AMP; Cyclic AMP | 2013 |
Role of preoperative adrenergic blockade with doxazosin on hemodynamic control during the surgical treatment of pheochromocytoma: a retrospective study of 48 cases.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenergic alpha-1 Receptor Antagonists; Adult; Age Factors; | 2013 |
Doxazosin to treat hypertension: it's time to take it personally--a retrospective analysis of 19, 495 patients.
Topics: Aged; Antihypertensive Agents; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Retrospec | 2014 |
Spironolactone for resistant hypertension--hard to resist?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2015 |
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2015 |
ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Spi | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
Possible difference in the sympathetic activation on extreme dippers with or without exaggerated morning surge.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Circadian Rhythm; Doxazosin; Humans; Hypertension; Sym | 2009 |
Doxazosin and heart failure: to be or not to be.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricul | 2009 |
Spironolactone and doxazosin treatment in patients with resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Doxazosin; Drug Resistance; Drug Therapy, | 2009 |
Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies.
Topics: Animals; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Gene Expression; Gene Expres | 2009 |
Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Diuretics; Dose-Response Relationship, | 2009 |
Resistant hypertension. What is the best approach?
Topics: Antihypertensive Agents; Doxazosin; Drug Resistance; Humans; Hypertension; Mineralocorticoid Recepto | 2009 |
Silica in oral drugs as a possible sarcoidosis-inducing antigen.
Topics: Administration, Oral; Antigens; Antihypertensive Agents; Bisoprolol; Causality; Chemistry, Pharmaceu | 2009 |
Molecular mechanisms regulating urogenital expression of nitric oxide synthase in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Calcium Channel Blockers; Doxazosin; Gene Expression; Gene Ex | 2009 |
[Ejaculatory disorder caused by doxazosin administration for blood pressure control in patient with pheochomocytoma].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Doxazosin; Ej | 2009 |
The effect of doxazosin mesilate on cerebral blood flow in patients with hypertension and chronic cerebral infarction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Ca | 2009 |
Identification of potential therapeutic targets in hypertension-associated bladder dysfunction.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Doxazosin; Gene Expression; Gene Expression | 2010 |
Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.
Topics: Aged; Antihypertensive Agents; Doxazosin; Female; Heart Failure; Hospitalization; Humans; Hypertensi | 2009 |
Pheochromocytoma in children and adolescents.
Topics: Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Adrenergic alpha-Antagonists; Child; Doxazosin; | 2009 |
Impact of arterial stiffness reduction on urinary albumin excretion during antihypertensive treatment: the Japan morning Surge-1 study.
Topics: Aged; Albuminuria; Ankle Brachial Index; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Bra | 2010 |
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Combina | 2010 |
Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients.
Topics: Antihypertensive Agents; Chromatography, Liquid; Doxazosin; Humans; Hypertension; Patient Compliance | 2010 |
Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagon | 2011 |
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; F | 2013 |
Summaries for patients. Blood pressure drugs and heart failure.
Topics: Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Chlorthalidone; Double-Blind Method; D | 2002 |
Doxazosin and ALLHAT trial: a response.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Doxazos | 2002 |
[Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Doxazosin; Fem | 2002 |
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabete | 2002 |
[Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2003 |
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabete | 2003 |
[Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucos | 2002 |
[Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2003 |
Diuretics: older, cheaper, better.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines | 2003 |
[ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Dose-Resp | 2003 |
[The incidence, features of the course, and treatment of arterial hypertension in patients with prostate hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Diuresis; Doxazosin; Heart Rate; Humans; Hyperte | 2003 |
Effects of preweaning doxazosin treatment on adult pressure in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Animals, Suckling; Blood Pressure; Cardiomegaly; Doxazosin; F | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Flow cytometric analysis of platelet activation in hypertensive patients. Effect of doxazosin.
Topics: Adult; Antihypertensive Agents; Doxazosin; Female; Flow Cytometry; Follow-Up Studies; Humans; Hypert | 2003 |
[Possibility of predicting the use of doxazosin in the treatment of arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Hemodynamics; Humans; Hypertension; Male; Middle Age | 2003 |
Clinical application of wave intensity for the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Doxazosi | 2004 |
[Effects of monotherapy with an alpha1-adrenoblocker doxazosin and its combination with beta1-adrenoblocker atenolol on hemodynamics, reversible myocardial ischemia in postmyocardial infarction patients with arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 2003 |
Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Uti | 2004 |
Relapse of Graves' disease in a patient with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antithyroid Agen | 2003 |
[Alfadil and heart failure--clinical conclusions do exist!].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Doxazosin; Drug Information Services; Heart Failu | 2003 |
[Treatment of hypertension in a clinical trial. Depot alpha 1 blocker simplifies dosing].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Delayed-Action Prep | 2003 |
[Doxazosin and heart failure: a clinical conclusion is wanted].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertensio | 2003 |
[Alfadil--positive documentation when it comes to safety is missing].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Documentation; Doxazosin; Drug Information Se | 2003 |
[ALLHAT--remaining questions await answers].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Benzothiadiazines; Calcium Channel Blockers; | 2004 |
[Choice of antihypertensive agent--insignificant role of doxazosin (Alfadil). How are evidence-based recommendations implemented?].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Contraindications; Doxazosin; Evidence-Based | 2004 |
Prostate apoptosis after doxazosin treatment in the spontaneous hypertensive rat model.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Apoptosis; Caspases; Cohort Studies; Doxazos | 2004 |
Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Albuminuria; Angiotensin-Conv | 2004 |
[Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension].
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Catecholamines; Doxazosin; Drug Resistance; Fe | 2004 |
[Use of alpha-adrenoblockers in therapy of benign prostatic hyperplasia in patients with arterial hypertension].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antineoplastic Agents | 2004 |
Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraga
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Atenolol; Blood Pr | 2004 |
The vascular effects of doxazosin in hypertension complicated by metabolic syndrome.
Topics: Dose-Response Relationship, Drug; Doxazosin; Drug Administration Schedule; Endothelium, Vascular; Fo | 2005 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Rec | 2005 |
Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Blood Pre | 2005 |
Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiomegaly; Co | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Delayed-Action Preparations; Dose-Response | 2006 |
[Doxazosine associated to renin-angiotensin blockers and calcioantagonists in chronic renal failure patients].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Doxazosin; Female; Humans; Hypertension; Kidney F | 2005 |
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study?
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as | 2006 |
Cytoplasmic free calcium mobilization in platelets, expression of P-selectin, phosphatidylserine, and microparticle formation, measured by whole blood flow cytometry, in hypertensive patients. Effect of doxazosin GITS.
Topics: Antihypertensive Agents; Blood Platelets; Calcium; Cell-Derived Microparticles; Cytoplasm; Doxazosin | 2006 |
Doxazosin gastrointestinal therapeutic system: a clinical perspective.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Drug Therapy, Combination; Gastroi | 2006 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
Association of IFIS and vasodepressor medication.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertensi | 2006 |
Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Abdominal; Blood Pressure | 2006 |
The Japan Morning Surge-1 (JMS-1) study: protocol description.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure Determination; Circadian Rhythm; Clinical Proto | 2006 |
Intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Doxazosin; Humans; Hyal | 2006 |
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
[Anesthetic management for off-pump coronary artery bypass grafting in a patient with a pheochromocytoma and followed by the resection of the pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Anesthesia, Epidural; Anesthesia, Inhalation; | 2007 |
Comparative study of modified release alpha-blocker exposure in elderly patients with fractures.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Case-Control Studies; Delayed-Action Preparat | 2007 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adul | 2007 |
Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation.
Topics: Albuterol; Delayed-Action Preparations; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; | 2007 |
[Case of baroreflex failure after bilateral revascularization of the cervical carotid artery].
Topics: Adrenergic alpha-Antagonists; Aged; Baroreflex; Carotid Artery, Internal; Carotid Stenosis; Diagnosi | 2007 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular | 2008 |
New insights into the therapeutic management of morning hypertension with alpha1-adrenergic receptor blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Blood Pressure; Doxazosin; Hu | 2007 |
Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Bloo | 2007 |
Can doxazosin inhibit the hypertension-induced changes of endocrine cells in the stomach of spontaneously hypertensive rats?
Topics: Animals; Antihypertensive Agents; Doxazosin; Enteroendocrine Cells; Gastric Mucosa; Hypertension; Im | 2008 |
Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Humans; Hypertension; Male; | 1994 |
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin; | 1995 |
Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Erythrocytes; Female; Humans; H | 1995 |
Influence of alpha 1- and alpha 2-adrenoceptor antagonist therapy on the development of hypertension in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Doxazosin; Drug Therapy, Combination; Hyperte | 1993 |
Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood | 1995 |
[Efficacy and tolerance of doxazosin in the treatment of isolated systolic hypertension in hypertensive patients over 60 years of age].
Topics: Age Factors; Aged; Aged, 80 and over; Data Interpretation, Statistical; Doxazosin; Drug Evaluation; | 1995 |
Doxazosin studies provide clearer picture of blood pressure profiles.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Clinical Trials as Topic; Doxazosin; Female; | 1994 |
Selective alpha 1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension.
Topics: Administration, Oral; Adult; Blood Glucose; Blood Pressure; C-Peptide; Case-Control Studies; Doxazos | 1994 |
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
Topics: Coronary Disease; Doxazosin; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance | 1994 |
Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus.
Topics: Apolipoproteins; Blood Glucose; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hypertension; | 1994 |
Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gl | 1994 |
[Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].
Topics: Adult; Aged; Doxazosin; Female; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged | 1993 |
Peripheral alpha-agonists provide another option for hypertension.
Topics: Doxazosin; Humans; Hypertension; Patient Compliance | 1993 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium- | 1993 |
The alpha 1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagic hypotension in anesthetized hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cerebrovascular Circ | 1995 |
Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Doxazosin; Female; Humans; Hypertension; Male; M | 1996 |
Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Glucose; Case-Control Studies; Doxazosi | 1996 |
Chronic alpha-1-adrenergic blockade increases sympathoneural but not adrenomedullary activity in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Doxazosin; Epinephrine; Humans; Hypertension; N | 1995 |
Severe hypertension and cardiac failure associated with neuroblastoma: a case report.
Topics: Adrenergic alpha-Antagonists; Cardiomegaly; Catecholamines; Child, Preschool; Doxazosin; Female; Gan | 1996 |
[Long-term effects of a selective alpha 1-adrenergic inhibitor on right and left ventricular masses in patients with chronic pulmonary disease].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Carbon Dioxide; Chronic Disea | 1997 |
Drug treatment of hypertension in acute intermittent porphyria: doxazosin and amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Doxazosin; Drug Monitoring; Female; Humans; Hypertension; Middl | 1997 |
Drug induced psychosis with doxazosin.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hypertension; P | 1997 |
Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Doxazosin; Endothelium, Vascular; | 1997 |
Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Doxazosin; Fibrinolysis; Humans; Hyperten | 1998 |
[Effects of doxazosin and hydralazine on insulin sensitivity and sympathetic function in spontaneously hypertensive rat (SHR)].
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Doxazosin; Hydralazine; Hypertension | 1998 |
Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Ag | 1998 |
Benign prostatic hyperplasia and hypertension.
Topics: Antihypertensive Agents; Doxazosin; Erectile Dysfunction; Humans; Hypertension; Male; Prostatic Hype | 1998 |
Influence of baseline values. I: Effects on plasma total cholesterol and triglyceride levels during doxazosin treatment for hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Cholesterol; Doxazosin; Female; Humans; Hypertension; Male; Mi | 1998 |
Influence of baseline values. II: Variations in plasma lipoprotein fractions during doxazosin treatment for hypertension.
Topics: Adult; Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Doxazosin; Fe | 1998 |
Safety, efficacy, and lipid profile of doxazosin at a VA medical center.
Topics: Chicago; Doxazosin; Drug Monitoring; Hospital Bed Capacity, 500 and over; Hospitals, Veterans; Human | 1995 |
Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies.
Topics: Adult; Aged; Amidines; Antihypertensive Agents; Antioxidants; Bepridil; Biphenyl Compounds; Copper; | 1999 |
Hypertensive encephalopathy and nephrotic syndrome: a possible link?
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Azathioprine; Brain Diseases; Calcium Channel Blo | 1999 |
A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hype | 1999 |
Differential effects of losartan and doxazosin on vascular function in senescent spontaneously hypertensive rats.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Aging; Angiotensin II; Animals; Antihypertensive Agents | 1999 |
Platelet alpha2-adrenoceptor alterations in patients with essential hypertension are normalized after treatment with doxazosin but not propranolol.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Blood Platelet | 2000 |
Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Blood Viscosity; Doxaz | 1999 |
Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blood Pressure; Caspase 3; Caspases; Doxazosin; Hear | 2000 |
Doxazosin dropped from ALLHAT study.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; D | 2000 |
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Diur | 2000 |
Diuretics vs. alpha blockers.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Ca | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |
Effect of antihypertensive therapy on renal injury in type 2 diabetic rats with hypertension.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Typ | 2000 |
Hypertension and alpha-adrenergic blockers: preliminary ALLHAT results.
Topics: Adrenergic alpha-Antagonists; Aged; Canada; Chlorthalidone; Diuretics; Doxazosin; Female; Humans; Hy | 2000 |
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Drugs, blood pressure linked: study.
Topics: Adrenergic alpha-Antagonists; Diuretics; Doxazosin; Humans; Hypertension; Risk Assessment; Survival | 2000 |
Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Doxazosi | 2001 |
Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Viscosity; Doxazosin; Female; Hematocrit; Hemodynamics; Hemorh | 1999 |
Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Platelets; Cell Size; Doxazosin; Female; Humans; Hyperten | 2001 |
The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy.
Topics: Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Do | 2001 |
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Ag | 2001 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
Low-dose alpha/beta blockade in the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Angiotensin- | 2001 |
[Doxazosin and soluble guanylate cyclase in a rat model of hypertension].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Doxazosin; Guanylate Cycla | 2001 |
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cause of Death; Chlorthalidone; Doxazos | 2001 |
Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Biological Availability; Blood P | 2001 |
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is C
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hyper | 2001 |
Heart lines. Cardura update.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Diuretics; Doxazosin; Heart Failure; Humans; | 2001 |
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Topics: Aged; Antihypertensive Agents; Apolipoproteins; Blood Glucose; Blood Pressure; C-Peptide; Cholestero | 2001 |
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Humans; | 2001 |
[Effect of doxazosin on postural changes in blood pressure using a multibiomedical recorder].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitori | 2001 |
Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Aorta; Cyclic GMP; Doxazosin; Endothelium, Vas | 2002 |
The choice of antihypertensive drugs in patients with erectile dysfunction.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype | 2002 |
Doxazosin, an inferior antihypertensive agent?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cont | 2002 |
A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chemistry, Pharmaceutical; Clinical Trials as Topic; | 2002 |
[Doxazosin, of modified liberation, in hemodialyzed patients].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Doxazosin; Female; Humans; Hypertension; Ma | 2002 |
A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats.
Topics: Anesthesia; Animals; Antihypertensive Agents; Desoxycorticosterone; Disease Models, Animal; Dose-Res | 1992 |
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomeg | 1992 |
Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; | 1992 |
Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Compliance; Doxazosin; Female; Humans; Hy | 1992 |
Combination of nifedipine and doxazosin in essential hypertension.
Topics: Aged; Analysis of Variance; Angiotensin II; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug | 1992 |
Doxazosin: alternative antihypertensive treatment.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hyper | 1992 |
Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Heart Rate; Human | 1992 |
Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension.
Topics: Adult; Blood Glucose; Cholesterol; Doxazosin; Female; Glucose; Humans; Hypertension; Insulin; Lipids | 1992 |
New alpha 1-adrenergic blocker offers once-daily dosing.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Prazos | 1991 |
Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin. A symposium. London, England, January 26, 1990. Proceedings.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1991 |
The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study.
Topics: Adult; Antihypertensive Agents; Blood Platelets; Dose-Response Relationship, Drug; Doxazosin; Female | 1991 |
Doxazosin for treatment of hypertension.
Topics: Antihypertensive Agents; Blood Glucose; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
Diabetes mellitus and hypertension: a physiologic basis for a rational therapeutic approach.
Topics: Antihypertensive Agents; Biological Transport; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1991 |
[The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
Topics: Adult; Blood Pressure; Doxazosin; Fibrinogen; Humans; Hypertension; Lipids; Middle Aged; Plasminogen | 1991 |
Prolonged photostress macular recovery after reduced blood pressure.
Topics: Adaptation, Physiological; Adult; Aerospace Medicine; Antihypertensive Agents; Blood Pressure; Doxaz | 1991 |
The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol; Cost-B | 1990 |
Hypertension, coronary risk and alpha-blockade.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Fact | 1990 |
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dox | 1990 |
Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Female; Fibrinogen; Hemodynamics; Humans; Hypertensi | 1990 |
The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Doxazosin; F | 1990 |
[Doxazosin--therapeutic advantages in hypertension].
Topics: Doxazosin; Humans; Hypertension; Prazosin | 1990 |
[Doxazosin for the treatment of arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Doxazosin; Drug Administrati | 1990 |
Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Catecholamines; Creatinine; Doxazosin; Electrolytes; Female; Hea | 1987 |
Effects of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Collagen; Dose-Response Relationship, Drug; D | 1987 |
Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorothiazide; Doxazosin; Female; Half-Life; | 1989 |
Alpha-blockade for hypertension: indifferent past, uncertain future.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Drug Evaluation; Humans; Hypertension; Prazosi | 1989 |
Clinical settings for selective alpha-adrenergic receptor inhibition: rationale and management strategies. Proceedings of a symposium. Naples, Florida, October 13 to 16, 1988.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Asthma; Blood Pressure; Doxazosin; Female; Forced Expirat | 1989 |
Plethysmographic effects of doxazosin in essential hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug | 1989 |
Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Antihypertensive Agents; Blood Pressure; Doxazos | 1986 |
Role of alpha 1- and alpha 2-adrenergic receptors in the human hypertensive kidney.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Humans; Hypertension; Kidney; Middle Aged; Prazosin; | 1987 |
Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Clinical experience with doxazosin in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Dru | 1988 |
Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 1988 |
Alpha 1-adrenoreceptor blockade in hypertension: pharmacological and clinical profile of doxazosin. Proceedings of an international symposium. Venice, Italy, 14 June 1985.
Topics: Animals; Antihypertensive Agents; Doxazosin; Humans; Hypertension; Prazosin | 1986 |
Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Doxazosin; Female; Hemodynamic | 1986 |
A symposium: Doxazosin: coronary artery disease risk factor management. June 7, 1986, Frankfurt, Germany.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk | 1987 |
Doxazosin: A distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Proceedings of a symposium. Hamburg, West Germany, January 30, 1988.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1988 |
Effect of sympathetic stimulation and intrarenal alpha-blockade on the secretion of renin by the human kidney.
Topics: Adult; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Isometric Contraction; Kidney; Male; M | 1985 |